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Age-related maculopathy (ARM) is the leading cause of blindness in the elderly. Although beneﬁcial therapeutic strategies have
recently begun to emerge, much remains unclear regarding the etiopathogenesis of this disorder. Epidemiologic studies have
enhanced our understanding of ARM, but the data, often conﬂicting, has led to diﬃculties with drawing ﬁrm conclusions with
respect to risk for this condition. As a consequence, we saw a need to assimilate the published ﬁndings with respect to risk factors
for ARM, through a review of the literature appraising results from published cross-sectional studies, prospective cohort studies,
case series, and case control studies investigating risk for this condition. Our review shows that, to date, and across a spectrum
of epidemiologic study designs, only age, cigarette smoking, and family history of ARM have been consistently demonstrated to
represent risk for this condition. In addition, genetic studies have recently implicated many genes in the pathogenesis of age-
related maculopathy, including Complement Factor H, PLEKHA 1, and LOC387715/HTRA1, demonstrating that environmental
and genetic factors are important for the development of ARM suggesting that gene-environment interaction plays an important
role in the pathogenesis of this condition.
Copyright © 2009 Paul P. Connell et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Age-related macular degeneration (AMD), the late stage of
age-related maculopathy (ARM), is the leading cause of
blindness in white individuals over 65 years of age in the
Western world [1–3]. According to large population-based
studies, the prevalence of AMD is 0.2% in persons aged 55
to 64 years, and rises to 13% in individuals 85 years of age or
older.
The burden of AMD to individuals and to society is
expected to rise as a result of an increase in life expectancy,
reduced birth rates, and the consequential demographic
shift towards an elderly population [3]. The increasing
socio-economic impact of AMD, coupled with its unclear
pathogenesis and limited available therapies, has prompted
investigators to carry out studies designed to identify risk
factors for this condition.
Risk factors for ARM may be classiﬁed as modiﬁable
and nonmodiﬁable. Possible modiﬁable risk factors for ARM
include smoking, body mass index, cumulative sunlight
exposure, diet, alcohol consumption, and cardiovascular
disease.PossiblenonmodiﬁableriskfactorsforARMinclude:
age, family history of ARM (early and/or late), iris color, and
refractive error.
Any review of the literature assessing possible risk factors
for ARM should comment upon the nature of the designs of
thestudiescited,andontherelativestrengthsandlimitations
of such designs [4]. Cross-sectional study design, in which
we take a sample of some narrowly deﬁned population at
one point in time, can give information on prevalence of a
speciﬁc disease, but gives little indication of cause and eﬀect.
Furthermore, in certain disease states, the studied end-point
may be so infrequent, thus a very large sample size is often
necessary. A prospective study is one that is longitudinal
in nature with diﬀerent time points studied. However, such
studies are sometimes limited where the population studied
is too selective, and hence not representative of the total
population. A prospective study design is generally favored
over a cross-sectional design when attempting to establish
cause and eﬀect [4].
Thus, in this article, we review the literature germane
to risk for ARM, as determined by studies of various2 Journal of Ophthalmology
design, including case series, cross-sectional, cohort, and
case-control studies (Tables 1 and 2). Further, the relative
meritsandlimitationsofvariedstudydesignsininvestigating
risk for a condition such as ARM are also discussed. These
studies were chosen for their large sample sizes and the
standardized manner in which they have assessed ARM. We
also cite nonpopulation-based studies, where necessary, as
background material. Of note, the majority of studies relate
to white populations [5].
Most of the cited studies have utilized a grading system
of ARM, consistent with the International Classiﬁcation
and Grading System for ARM and AMD. According to this
classiﬁcation, a diagnosis of early ARM is made in the
presence of soft drusen (≥63μm) within the macular area
and/or areas of retinal pigment epithelium (RPE) changes
(hyperpigmentation and/or hypopigmentation). The late
stage of ARM, known as age-related macular degeneration
(AMD), is characterized by at least one of the following
features: geographic atrophy, RPE detachment (neovascular
or nonneovascular in origin), choroidal neovascularization,
with or without its sequelae (hemorrhagic detachment of
either the RPE or neurosensory retina, presence of subretinal
orsub-RPEhemorrhageorsubretinalﬁbrosis).Geographical
atrophy (GA) is deﬁned as a discrete area of hypopigmenta-
tion or depigmentation or apparent absence of the RPE in
which choroidal vessels are more visible than in surrounding
areas, and must be at least 175μm in diameter. Cases with
minimal subretinal ﬁbrosis and widespread surrounding
atrophywerealsoclassiﬁedasneovascularAMD,becausethis
appearance was considered to indicate previous choroidal
neovascularization [5, 6].
In this review article we have, where possible in the
context of the grading systems used in the cited studies,
distinguished between early ARM and late ARM (AMD). All
of the cited studies comment on the prevalence of ARM,
deﬁned by the appearance of the designated lesion(s) at
the time of the study examination. Where incidence of
ARM was studied, it was identiﬁed by the appearance of a
designated lesion at followup examination a number of years
following the baseline examination where no such ﬁndings
were present.
2.GeneticPredisposition
Studying ARM as a genetic disease is diﬃcult due to the
inherentlyage-relatednatureofthedisease[7,8].Age-related
maculopathy occurs later in life, and therefore only one
generation in the aﬀected age range is available for study,
as parents may be deceased and the children too young to
exhibitthiscondition.ThephenotypicheterogeneityofARM
also presents a challenge, because it is possible that diﬀerent
genes underlie diﬀerent phenotypes, and therefore genetic
studies may fail to identify any one causative gene or region,
if all stages of ARM are studied in a collective fashion [9].
Sample size may also be a problem if one speciﬁc form of
ARM is chosen for analysis, due to the infrequency of the
end-point studied. In spite of these diﬃculties, investigators
in recent years have greatly enhanced our understanding of
the genetic basis of ARM.
Many human diseases have a genetic basis, mediated
through DNA sequence variation [8, 10]. Such DNA alter-
ations may be represented by changes in a single nucleotide
or an entire chromosome. Single nucleotide polymorphisms
(SNPs) are by far the most common form of DNA sequence
variation [8, 10]. Such changes result in altered forms of a
particular gene, known as alleles. Diﬀerent alleles may pro-
duce variations in inherited characteristics. These variants
may either enhance or reduce an individual’s predisposition
fordevelopingaparticulardisease,ortheymayhavenoeﬀect
on overall disease risk [11].
With regard to ARM, there is now strong evidence sup-
porting the role of genetic background in the development
of ARM [8, 10]. The initial evidence supporting the role
of heritability in the pathogenesis of ARM was provided by
observational familial aggregation studies, twin studies, and
segregation analyses [12–15].
Familial Aggregation Studies. Familial aggregation studies
are designed to identify if the risk for a certain condition
is higher in individuals related to the aﬀected individual,
when compared to unrelated individuals [16]. One of the
ﬁrst familial aggregation studies undertaken to ascertain the
risk of ARM posed by having a positive family history of
disease was performed by Seddon et al. [16]. In 1997, they
reported that the prevalence of ARM in ﬁrst-degree relatives
of individuals with any form of ARM (atrophic or exudative)
was over twice that in individuals who had no family history
of disease.
During the baseline examination of the Beaver Dam Eye
Study, cross-sectional information was gathered regarding
the siblings of participants [17]. Five years later, incident
ARM was evaluated for those siblings who had no evidence
of the disease at baseline. The odds ratios (ORs) for
the sibling developing the lesion, when compared with a
control proband, were 8.18 for retinal pigment epithelial
hypopigmentation, 3.59 for retinal pigment epithelial hyper-
pigmentation, and 10.32 for neovascular ARM [17].
The Rotterdam Study provides two population-based
familial aggregation analyses, which have reported that a
positive family history of ARM represents risk for this
condition [12, 13]. In the ﬁrst case control study, ﬁrst-degree
relatives of 87 patients with late ARM were compared with
ﬁrst-degree relatives of 135 control subjects (none of whose
ﬁrst-degree relatives suﬀered from this condition) [15]. The
prevalence of early ARM and late ARM was signiﬁcantly
higher in relatives of patients with late ARM, independent
of other risk factors. The second familial aggregation study,
within the Rotterdam Eye Study, assessed the extent of
heterogeneity of genetic risk of ARM among families [12].
It was reported that considerable diﬀerences in risk of ARM
heritability between individual families existed, and that the
proportion of families at high risk was relatively small.
TwinStudies. Severaltwinstudieshavealsoyieldedinforma-
tionregardingthenatureofheritabilityofARM[61,62].The
ﬁrst of these, published in 1988, reported on severe ARM in
monozygotic twins [61, 62]. This study also demonstrated
disease in four of the thirteen twin pairs’ siblings [62]. InJournal of Ophthalmology 3
Table 1: Large epidemiologic studies investigating risk for ARM.
Study Location Design No. of participants
Beaver Dam Eye Study [17–22] USA (1988–2005)
Cross-Sectional 4926
Prospective
3684 (5-year)
2764 (10-year)
2119 (15-year)
Blue Mountains Eye Study [23–25] Australia (1992–2004)
Cross-Sectional 3654
Prospective 2335 (5-year)
1952 (10-year)
Rotterdam Study [23, 26–28] Holland (1990–2004)
Cross-Sectional 6418
Prospective
4953 (2-year)
3406 (6.5-year)
2387 (11-year)
Pathologies Oculaires Liees a L’Age
[29, 30]
France (1995–2000) Cross-Sectional 2584
Prospective 1642 (3-year)
Los Angeles Latino Eye Study [31] USA (2000–2003) Cross-Sectional 6357
Melbourne Visual Impairment
Project [32, 33]
Australia (1992-1999) Cross-Sectional 5147
Prospective 3271 (5-year)
Reykjavik Eye Study [34–36] Iceland (1996–2001) Cross-Sectional 1045
Prospective 846 (5-year)
Beijing Eye Study [37] China (2001) Cross-Sectional 4439
Copenhagen City Eye Study [38–40] Denmark (1986–2002) Cross-Sectional 946
Prospective 359 (14-year)
Andhra Pradesh Eye Disease Study
[41]
India (1996–2000) Cross-Sectional 3723
Barbados Eye Studies [42–45] Barbados (1987–2003)
Cross-Sectional 4631
Prospective 3427 (4-year)
2793 (9-year)
Salisbury Eye Evaluation Project
[46]
USA (1993) Cross-Sectional 2520
Proyecto VER [47] USA (1997–1999) Cross-Sectional 4774
Baltimore Eye Survey [5] USA (1985–1988) Cross-Sectional 5308
Aravind Comprehensive Eye Survey
[48]
India (1995–1997) Cross-Sectional 5150
European Eye Study [1, 49] 7 European Countries (2000–2003) Cross-Sectional 5040
Hisayama Study [50, 51] Japan (1998–2003) Cross-Sectional 1482
Prospective 961 (5-year)
Framingham Eye Study [52, 53] USA (1973–1975) Cross-Sectional 2940
National Health and Nutrition
Examination Survey I [54]
USA (1971–1972) Cross-Sectional 3056
National Health and Nutrition
Examination Survey III [55, 56]
USA (1988–1994) Cross-Sectional 8270
Cardiovascular Health Study
[57, 58]
USA (1997–1998) Cross-Sectional 2361
Atherosclerosis Risk in
Communities Study [19, 59, 60]
USA (1993–1995) Cross-Sectional 11532
MRC Trial of Assessment and
Management of Older People in the
Community [2]
UK (1996–2000) Cross-Sectional 139004 Journal of Ophthalmology
Table 2: Risk factors for ARM examined in the cited studies.
Genetic predisposition
Family history of ARM
Complement Factor H gene
Apolipoprotein E gene
LOC gene
Cardiovascular disease
Clinical Evidence of Atherosclerosis
Angina/Heart attack/Stroke
Subclinical evidence of atherosclerosis
Carotid atherosclerosis
Aortic atherosclerosis
Cigarette smoking
Diabetes mellitus
Hypertension and associated disease
Ischemic cerebral white matter changes
Abnormalities of the retinal vasculature
Cholesterol
Total cholesterol
Low-density Lipoprotein (LDL) cholesterol
High-density Lipoprotein (HDL) cholesterol
Obesity
Female sex hormones
Endogenous estrogen exposure
Age at menarche
Age at menopause
Number of pregnancies
Exogenous estrogen exposure
Oral contraceptives
Hormone replacement therapy
Novel risk factors for atherosclerosis
Lipid-related Factors
Apolipoproteins
Lipoproteins
Inﬂammatory markers
C-reactive protein
Interleukins
Serum Amyloid A
Vascular and Cellular Adhesion Molecules
White Blood Cell Count
Homocysteine/Folate/Vitamin B12/Vitamin B6
Infectious agents
Cytomegalovirus
Helicobacter pylori
Chlamydia pneumoniae
Indicators of Inﬂammation
Systemic Diseases with Inﬂammatory Components
Gout
Emphysema
Anti-inﬂammatory Medications
Table 2: Continued.
NSAIDs
Steroids
Markers of Systemic Inﬂammation
White Blood Cell Count
Serum Albumin
Plasma Fibrinogen
C-reactive Protein
Complement Factor H Y402H Polymorphism
CRP Haplotype
Serum Amyloid A
Interleukin-6
T u m o rN e c r o s i sF a c t o r - α
Markers of Endothelial Dysfunction
Intercellular Adhesion Molecule-1
E-Selectin
Indicators of Oxidative Stress
Anti-oxidants
Vitamin C
Vitamin E
Vitamin A
Carotenoids
Lutein
Zeaxanthin
α-a n dβ-Carotene
β-Cryptoxanthin
Lycopene
Enzymes
Plasma Glutathione Peroxidase
Superoxide Dismutase
Trace Elements
Zinc
Pro-oxidant status
Dietary fat intake
Total fat
Saturated fat
Polyunsaturated fat
Fish/Fish oils
Visible Light Exposure
Sunlight
Ultraviolet-B
Ocular Factors
Refractive Error
Emmetropia
Myopia
Hypermetropia
Iris Color
Cataract
Nuclear Sclerosis
Cortical Lens OpacitiesJournal of Ophthalmology 5
Table 2: Continued.
Posterior Subcapsular Cataracts
Cataract Surgery
Miscellaneous Factors
Alcohol Consumption
Beer
Wine
Spirits
Medication Use
Estrogens
Lipid-lowering Agents
CNS Medications
Non-steroidal Anti-Inﬂammatory Medications
Anti-hypertensive Medications
Coﬀee Consumption
Frailty
Physical Activity
1994, Meyers et al. demonstrated a concordance rate of
100% for ARM in 23 monozygotic twin pairs, and a 25%
concordance rate in eight dizygotic twin pairs [61, 62].
By comparison, the concordance amongst age- and sex-
matched individuals from nontwin subjects ranged from 16
to 25%. Hammond et al. who investigated 226 monozygotic
twin pairs and 280 dizygotic twin pairs in a UK study
demonstrated an overall prevalence of ARM of 14.6% in
their study group, with concordance rates of 37% and 19%
for monozygotic and dizygotic twin pairs, respectively [13].
Interestingly, they found that there were diﬀerences in the
heritability of diﬀerent phenotypes of ARM, with the fundal
appearance of ≥20 hard drusen being dominantly inherited
(and 81% genetically determined). In 2005, Seddon et al.
reported on a study of 840 elderly male twins, consisting
of 210 monozygotic and 181 dizygotic complete twin pairs,
and 58 singletons [63]. They devised a model to partition
variation in risk for development of ARM into additive
genetic, common environment, and unique environment
components. Using this model, they reported that genetic
factors played a signiﬁcant role in the etiology of ARM, and
accounted for 46–71% of the variation in the overall severity
of the disease.
Genes Involved in ARM Pathogenesis. The evidence, desc-
ribed earlier, supporting a genetic role in the development
of ARM led to a search for a susceptibility gene, or genes,
responsible for ARM.
Complement Factor H. In early 2005, three separate research
groups independently identiﬁed a variant in the complement
factor H (CFH) gene, known as the Y402H polymorphism,
which exerts a strong inﬂuence on the risk of developing
ARM [64–66]. This variant, in which histidine replaces
tyrosine at position 402 of the amino acid sequence of the
CFH gene on chromosome 1q31, was associated with odds
ratios ranging from 2.45 to 3.33 for all stages of ARM,
and odds ratios of 3.45 to 7.4 for late ARM. These studies
suggested that almost half of all cases of ARM in older
individuals could be attributable to this variant of the CFH
gene. Since that report, it has been found that there are
ﬁve haplotypes at the CFH locus, three of which confer
increased risk for ARM, and two of which are protective
[65, 66]. The SNP originally associated with increased risk
for ARM, responsible for the CFH Y402H variant allele, is
rs1061170. A recent article suggests that a 3-SNP haplotype
comprising rs1061147, rs1061170, and rs2274700 exhibits
the strongest association with advanced ARM, even more so
than the rs1061170 SNP alone [66, 67]. It is also interesting
to note that polymorphisms of the CFH gene may be more
closely associated with risk for geographic atrophy than
for neovascular ARM [68]; however, not all studies have
reported this preferential association with the GA form of
ARM [69, 70].
Interestingly, interaction between tobacco use and the
Y402 H gene has been recently reported, although followup
studies have not replicated such ﬁndings (reported in what
follows) [71, 72].
PLEKHA1 and LOC387715/HTRA1. Further two reports in
2005 identiﬁed other susceptibility loci, on chromosome
10q26, associated with increased risk for ARM [73, 74].
This region of chromosome 10q26 overlaps with three
genes: PLEKHA1, LOC387715, and HTRA1, which show
signiﬁcant linkage disequilibrium (LD) with one another
[75]. In particular, there is almost complete LD between
the LOC387715 and HTRA1 domains [75]. This degree of
LD has made it diﬃcult to determine precisely which of
these three genes is primarily responsible for the risk of
ARM, attributable to this region of chromosome 10q26.
However, a recent report by Kanda et al. suggests that a
singleSNP(rs10490924)thatchangesthecodingsequenceof
the hypothetical LOC387715 gene can account for all of the
association between chromosome 10q26 and risk for ARM
[76]. The precise role of the LOC387715 gene has yet to
be elucidated, but it is believed to relate to mitochondrial
function [76]. Of note, one of the original reports on the
LOC387715 gene found that homozygosity for this gene,
in combination with homozygosity for the Y402H variant
of the CFH gene, confers an odds ratio of 57.6 (95%
CI: 37.2–89.0) for the development of ARM, compared to
the baseline nonrisk genotype [77]. It is also noteworthy
that there appears to be a multiplicative eﬀect on risk for
ARM with each additional LOC387715 variant allele, in that
heterozygosity confers an odds ratio for development of
ARM of 2.83 (95% CI: 1.91–4.20), whereas homozygosity
confers an odds ratio of 32.83 (95% CI: 12.53–86.07).
However, not all studies have demonstrated such a dramatic
multiplicative eﬀect [78].
Apolipoprotein E. Apolipoprotein E gene (ApoE) codes for
apolipoproteins, which are major transporters of lipid and
cholesterol in the nervous system [79–81]. ApoE is polymor-
phic with three common isoforms: E2, E3, and E4, which
are coded for by three separate alleles: ε2, ε3, and ε4. As
a result, six common phenotypes exist: three homozygous6 Journal of Ophthalmology
phenotypes (ε2/ε2, ε3/ε3, ε4/ε4) and three heterozygous
phenotypes (ε2/ε3, ε2/ε4, ε3/ε4) [82].
Interestingly,ApoEisaubiquitouscomponentofdrusen,
and clinical manifestations of retinal degeneration are exhib-
ited in Apolipoprotein E-deﬁcient mice that carry an ApoE
gene that has been inactivated by gene targeting [83, 84].
Most studies, but not all, investigating the role of the ApoE
gene with respect to the risk for ARM have reported that the
ε4 allele (which codes for the E4 variant) is less prevalent
(thus appearing protective) among suﬀerers of ARM when
compared with a control proband [14, 80, 85–89]. In
1998, a nested case-control study within the Rotterdam
Study demonstrated that the ε4 allele was associated with
decreased risk of ARM, while the ε2 allele was associated
with a slightly increased risk of ARM [14, 88]. In 2006,
the Atherosclerosis Risk in Communities Study found no
evidence of a strong association between the ApoE gene
and early ARM in middle-aged persons [90]. In 2007, the
Cardiovascular Health Study demonstrated that the ε2a l l e l e
might be associated with an increased risk of developing
late ARM in white people aged 65 years and over, and that
the ε4 allele appears to confer some protection against the
development of late ARM (although this association was not
statistically signiﬁcant) [82].
Other Genes. Other genes recently discovered to be associ-
ated with an increased risk for ARM include the complement
factor B gene (BF), the complement component 3 gene (C3),
and the complement component 2 gene (C2) [69, 91]. In
conjunction with the increased risk of ARM association with
the CFH variant gene, these recently discovered complement
genes are consistent with the view that inﬂammation and the
control of inﬂammation are important in the pathogenesis
of ARM [92]. Many other candidate genes have been
investigated for an association with ARM, including ABCA4,
HEMICENTIN-1 (ﬁbulin 6), PON1, ELOVL4, VLDLR, and
ACE, with inconsistent results to date [93].
In conclusion, over the past decade, numerous studies
have attempted to identify susceptibility genes for AMD.
The discovery of a risk variant within the CFH gene and
recent ﬁndings for loci PLEKHA1/LOC387715, Apo E, and
BF/C2 have increased our knowledge particularly in relation
to elucidating the complex gene-environment interaction in
the pathogenesis of this disease. Future research is likely to
clarify the exact role of these genes and identify additional
susceptibility genes.
3.CardiovascularDisease
Cardiovascular disease includes coronary heart disease,
cerebrovascular disease, and peripheral arterial disease.
Atherosclerosis is responsible for the majority of cases of
cardiovascular disease [94, 95]. More speciﬁcally, atheroscle-
rosis is the most prevalent disease in the modern era, and its
thrombotic complications are responsible for an exceedingly
high number of deaths and disabilities [94, 96].
As early as 1937, it was hypothesized that ARM may
be part of an underlying systemic vascular process and
thereforeassociated with cardiovascular disease [96–99]. Ini-
tially, however, epidemiologic studies failed to demonstrate
consistent or conclusive results. Interest in the relationship
between cardiovascular disease and ARM was renewed
following the publication of a work in 1990s that showed
a strong positive association between carotid atherosclerosis
and ARM [96, 100]. Other studies have since provided
further evidence supporting the view that cardiovascular
disease is etiologically important for ARM.
3.1. Hypothesis/Rationale. The vascular model proposes that
the progressive deposition of lipid, seen in atherosclerosis, is
the underlying cause of ARM [96, 97, 101]. This deposition
of lipid leads to its accumulation in the sclera and in
Bruch membrane, with a consequential increase in vascular
resistance [101]. This process would then interfere with the
metabolism of the RPE and lead to pigmentary abnormal-
ities, drusen formation, and, ultimately, the changes that
are represented by the clinical manifestations of ARM [102,
103]. Indeed, a number of in vitro studies support this
hypothesis. These include studies which have consistently
demonstrated that choroidal blood ﬂow in subjects with
ARM is lower than in age-matched controls [98, 100, 104,
105]. Furthermore, accumulation of extracellular cholesterol
inBruchmembraneresemblesthatfoundinthewallsoflarge
systemic arteries [102].
The inﬂammatory model of cardiovascular disease pro-
poses that local inﬂammatory responses are important in the
etiology of both macular drusen and drusen-like deposits
in arterial vessels [98, 106–108]. Several lines of evidence
support a role for inﬂammation in atherogenesis [106,
107]. Chronic inﬂammatory systemic disorders, including
rheumatoid arthritis and anklylosing spondylitis, are asso-
ciated with an increased incidence of cardiovascular disease
[107, 109]. Direct eﬀects and indirect sequelae of systemic
inﬂammation promote atherothrombotic vascular disease.
Indeed, an association between cardiovascular disease and
systemic markers of inﬂammation, including C-reactive
protein, IL-6, homocysteine, white blood cell count, D-
Dimer formation, factor VIII, has been demonstrated [107].
3.2. Epidemiologic Studies. Epidemiologic studies investigat-
ing a possible association between cardiovascular disease
and ARM have typically done so by focusing on three
main parameters: (1) clinical evidence of atherosclerosis in
subjects with and without ARM; (2) subclinical evidence of
atherosclerosis in subjects with and without ARM; (3) risk
factorsforatherosclerosisinsubjectswithandwithoutARM.
3.2.1. Atherosclerosis (Table 4). In most epidemiological
studies, clinically important atherosclerosis was deemed to
be present if subjects reported a history of angina, heart
attack, or stroke. Atherosclerosis does not correlate well with
cardiovascular events, which are largely atherothrombotic
[127], and therefore, studies investigating an association
between atherosclerosis and ARM must be interpreted with
full appreciation of this limitation. Indeed, the majority of
studies have failed to demonstrate an association betweenJournal of Ophthalmology 7
Table 3: Studies investigating the relationship between tobacco use and risk for ARM.
Study No. of cases Outcome
measure/risk factor Type of ARM Odds ratio or relative
risk
95% conﬁdence
interval
Cross-Sectional Studies
Beaver Dam Eye Study
[110]
4771 Current smokers
versus ex-smokers or
never smokers
Neovascular
AMD
2.50 1.01–6.20
(Females)
3.29 1.03–10.50
(Males)
Blue Mountains Eye Study
[24, 111]
3654 Current smoker
versus current
nonsmoker
Late ARM 3.92 2.07–7.41
Early ARM 1.75 1.20–2.54
Pathologies Oculaires Liees
aL ’ A g e[ 112]
2196 Current smokers Late ARM 3.6 1.1–12.4
Melbourne Visual
Impairment Project [26]
5147 Smoked Cigarettes for
longer than 40 years Late ARM 2.39 1.02–5.57
Rotterdam Study [113] 6174 Current smokers Neovascular
AMD 6.6 2.8–15.9
Los Angeles Latino Eye
Study [114]
5875 Ever smoked Late ARM 2.4 1.03–5.4
Ever smoked versus
never smoked
All AMD 2.4 P<. 5
Copenhagen Study
Denmark [39, 40]
773 Atrophic AMD 2.5 P<. 5
Neovascular
AMD 1.5 NS
Chesapeake Bay, Waterman
Study, USA [46]
769 Ever smokers versus
never smokers All AMD 0.61 (0.35–1.05)
Prospective studies
Blue Mountains Eye Study
[111, 115]
2335 Current smoker
versus never smoker
Geographic
atrophy 3.6 1.1–11.3
Any late ARM 2.5 1.0–6.2
Beaver Dam Eye Study
[22, 116]
2764
Current smoker Late ARM 0.51 0.18–1.46
Early ARM 1.37 0.98–1.94
Pooled data: Beaver Dam
Eye Study/Blue Mountains
Eye Study/Rotterdam Study
[23, 26]
14752 Current Smoker Late ARM 3.12 2.10–4.64
Pooled data: Beaver Dam
Eye Study/Blue Mountains
Eye Study/Rotterdam Study
[23, 26]
9523 Current smoker Late ARM 2.35 1.30–4.27
Physician’s Health Study,
USA [117]
Current smokers <
20/d versus never
smokers
All AMD 1.26 0.61–2.9
21157 Current smokers >
20/d versus never
smokers
All AMD 2.46 1.6–3.79
Neovascular
AMD 1.95 0.89–4.2
Nurse’s Health Study, USA
[118]
31843 Currrent smokers
versus never smoked All AMD 1.7 1.2–2.50
Hisayama Study [50] 961 Current or ex-smoker ARM 2.2 1.14–4.338 Journal of Ophthalmology
Table 3: Continued.
Study No. of cases Outcome
measure/risk factor Type of ARM Odds ratio or relative
risk
95% conﬁdence
interval
Case-Control Studies Case Con Current smokers
versus never smokers
France [112] 26 23 Neovascular
AMD 1.25 0.3–4.4
Eye Disease Case-Control
Study [119]
421 615 Neovascular
AMD 2.2 1.4–3.5
France [112]
1844 1844 All ARM/AMD 1.09 0.83–1.42
Neovascular
AMD 2.97 1.0–8.84
Japan [120] 56 82 Early ARM 1.25 1.09–1.44
Atrophic AMD 1.61 1.06–2.42
Age-related Eye Disease
Study [121]
340 111 Neovascular
AMD 1.91 1.57–2.33
5
Table 4: Studies investigating the relationship between hypertension and risk for ARM.
Study No. of cases Measure of risk factor Type of ARM Odds ratio or relative
risk
95% conﬁdence
interval
Cross-Sectional Studies
Hisayama Study [51] 1482 Hypertension (history
or examination) ARM 1.58 1.03–2.41
(Males)
Pathologies Oculaires Liees
aL ’ A g e[ 122]
2584
Systolic BP (per
10mm of Hg) Late ARM 1.19 0.98–1.43
Diastolic BP (per
10mm of Hg) Late ARM 0.98 0.72–1.35
Blue Mountains Eye Study
[24, 26] 3654
Previous diagnosis or
systolic BP > 160mm
Hg or diastolic BP >
90mm Hg
Early ARM 0.88 0.67–1.16
Late ARM 1.06
0.63–1.79
Beaver Dam Eye Study
[110]
4926 Hypertension
Neovascular
AMD 0.79 0.44–1.42
Geographic
atrophy 1.07 0.46–2.47
Prospective Studies
Pooled data: Beaver Dam
Eye Study/Blue Mountains
Eye Study/Rotterdam Study
[23, 26]
9523
Systolic blood
pressure (per 2mm of
Hg)
Late ARM 1.03 0.94–1.13
Diastolic blood
pressure (per 10mm
of Hg)
Late ARM 0.95 0.79–1.16
Rotterdam Study
[23, 123, 124]
4822
Elevated systolic
blood pressure (per
10mm Hg increase)
ARM 1.06 1.01–1.12
P u l s ep r e s s u r e( p e r
10mm Hg increase) ARM 1.09 1.02–1.15
Beaver Dam Eye Study
[125, 126]
2764 High systolic blood
pressure at baseline
Retinal pigment
epithelial
depigmentation
1.10 1.01–1.18
Neovascular
AMD 1.22 1.06–1.41Journal of Ophthalmology 9
reported clinically important atherosclerosis and the inci-
dence or prevalence of ARM [4, 18, 125, 128–130].
Three population-based epidemiological studies have
investigated whether evidence of subclinical atherosclerosis
is associated with risk for ARM, by using noninvasive
techniques to measure atherosclerotic vascular changes
[123, 129]. Typically, ultrasonography is used to assess the
carotid artery for the presence of atherosclerotic plaques,
which are deﬁned as focal thickenings of the vessel wall
relative to adjacent segments, and composed of calciﬁed or
noncalciﬁed components. Aortic plaques were diagnosed by
the detection of calciﬁc deposits in the abdominal aorta
by plain radiographic ﬁlms. Peripheral (lower extremity)
atherosclerosiswasassessedbycomparingthebloodpressure
in the posterior tibial artery to that of the brachial artery
(ABI: ankle-brachial index), and an index of <0.9 was
considered to indicate peripheral atherosclerosis [131].
In 1995, cross-sectional data from the Rotterdam Study
indicated that patients with subclinical carotid atheroscle-
rosis or peripheral atherosclerosis exhibited a signiﬁcantly
increased prevalence of late ARM [123, 131–133]. However,
this study did not assess early ARM, and one limitation
of the analysis rests on the small number of cases of late
ARM that was reported. Greater intima-media thickness
(another marker of subclinical disease) of the carotid artery
and the presence of aortic calciﬁcation were also found to
be associated with increased risk of incident late ARM in
longitudinal analyses of this cohort [134, 135]. Also, in 2003,
the Rotterdam Eye Study reported in its prospective arm an
association between subclinical atherosclerosis and incident
ARM [23, 131].
In 1999, the cross-sectional Atherosclerosis Risk in Com-
munitiesStudy,infact,demonstratedanassociationbetween
carotid atherosclerosis and prevalence of early ARM, but not
with carotid artery stiﬀness or pulse pressures (parameters
not measured in the Rotterdam Eye Study) [19, 59]. The
cross-sectional Cardiovascular Health Study failed to detect
an association between early ARM and carotid intima media
thickness [57].
The prospective arms of the Beaver Dam Eye Study
reported a statistically signiﬁcant association between a
higher pulse pressure and risk for late neovascular ARM (but
not atrophic late ARM) [126].
In summary, the results of studies designed to investigate
a possible association between atherosclerosis and risk for
ARM are inconsistent. However, it is worth bearing in mind
thatthesestudiesshouldbeinterpretedwithfullappreciation
of their limitations, including the poor relationship between
atherosclerosis and cardiovascular events, since cardiovas-
cular events were typically used in the reported studies as
a presumed indicator of underlying atherosclerosis. This
shortcoming needs to be addressed in the design of future
studies, if the relationship between atherosclerosis and ARM
is to be elucidated.
3.2.2. Cigarette Smoking (Table 3). Cigarette smoking has
been established as an important risk factor in the devel-
opment of cardiovascular disease [136], and has also been
found to be associated with increased risk for ARM [49, 114,
117, 137, 138]. The etiopathogenic mechanism underlying
the association between tobacco use and ARM remains
unclear. Smoking cigarettes may simply promote vascular
changes in the eye in a fashion similar to changes in the
systemic circulation and, as such, may simply represent an
antecedent common to both atherosclerosis and ARM [96,
97] .A l t e r n a t i v e l y ,an u m b e ro fo t h e rm e t a b o l i cf a c t o r sm a y
play a role in the etiopathogenic mechanism underlying the
association between tobacco use and the development of
ARM, and these include a parallel reduction in circulating
levels of antioxidants, coupled with an increased pro-oxidant
state caused by cigarette smoke [139]. It has also been
demonstrated that there is a relative lack of macular pigment
amongst tobacco users [140].
The limitations of studies attempting to investigate the
relationship between tobacco use and ARM warrant discus-
sion. First, potential confounders in such studies include
age and associations between tobacco use and other health
risk behaviours, such as poor diet and increased alcohol
consumption. Of the studies discussed in what follows, 15
have been adjusted for some of these potential sources of
confounding [49, 52, 72, 110–117, 119, 121, 138, 141].
However, only the 5-year and 10-year followup arms of the
Beaver Dam Eye Study adjusted for diet- and alcohol-related
factors [110, 116]. It should also be borne in mind that all
studies investigating the use of tobacco use and the risk for
ARM used subject-reported smoking data, and it is possible
that subjects underestimated the extent of their tobacco use.
Finally, loss of followup in longitudinal studies may also
aﬀect risk factor outcome data, because of smoking-related
morbidity and mortality, and therefore represent another
potential source of bias.
In epidemiologic studies, smoking history is typically
ascertained using an interviewer-administered question-
naire.Participantsareusuallyclassiﬁedasbeingnonsmokers,
former smokers, or current smokers. In a number of studies,
the total pack-years smoked by each participant was also
calculated, and this is deﬁned as the number of cigarettes
smoked per day divided by 20, and multiplied by the number
of years smoked [142].
The relationship between tobacco use and the preva-
lence and incidence of ARM has been investigated in
cross-sectional, prospective cohort and case-control studies
(Table 3)[ 49, 52, 72, 110–114, 116, 117, 119, 121, 138, 141].
Of seventeen studies, 13 have found a statistically signiﬁcant
association between cigarette use and at least one type of
ARM, with increased risk of this condition amongst current-
smokersandever-smokerswhencomparedwithnonsmokers
and never-smokers (relative risk/odds ratio 1.06–4.96) [32,
49, 110–112, 115–119, 121, 141, 143]. A signiﬁcant positive
association between smoking and ARM was observed in six
out of seven cross-sectional studies, three of four prospective
cohort studies, and four out of six case-control studies.
Pooled ﬁndings from three well-designed and well-executed
cross-sectional studies from Europe, Australia, and USA
have also convincingly demonstrated an association between
tobacco use and ARM [23, 26]. A prospective design
represents the best means for investigating whether smoking
leads to the ultimate development of ARM, and such studies10 Journal of Ophthalmology
have consistently demonstrated an increased incidence of
late ARM among smokers, although the association between
tobaccouseandtheincidenceofearlyARMislesscompelling
[32, 49, 110–113, 115, 117].
Of note, cigarette use increases the risk for both the
neovascularandatrophicformsoflateARM,butneovascular
ARM to a greater extent. Of the studies investigating the
possible association between cigarette use and late ARM, six
out of ten have found that tobacco use represents risk for
the development of neovascular late ARM [110, 113, 115,
119–121], and four of ﬁve have reported that cigarette use
is signiﬁcantly associated with risk of atrophic late ARM
[111, 115, 121, 143]. A smaller number of studies have
also conﬁrmed an association between tobacco use and the
incidence of both early and late ARM (Table 3)[ 32, 49, 110–
112, 115].
Furthermore, cigarette smoking appears to have a dose-
dependent relationship with risk for ARM, reﬂected in the
demonstration that the extent of risk rises with the number
of pack years smoked in the Physician’s Health Study and in
the Nurse’s Health Study [117, 118]. To date, eight studies
have investigated this dose-response relationship between
cigarette use and ARM, and all but one (the 10-year followup
arm of the Beaver Dam Eye Study) identiﬁed a positive
relationship [20, 32, 112, 113, 117, 118, 120, 128].
Only one study to date has investigated whether tobacco
use inﬂuences the age of onset of ARM. In the Blue
Mountains Eye study, it was reported that participants who
were free of late ARM at baseline but who were current
smokers ultimately developed ARM on average 10 years
earlier than nonsmokers, who also exhibited no signs of
disease at baseline [115].
Finally, there is a growing body of evidence to suggest
that cessation of cigarette smoking leads to a subsequent
reduction in the risk for ARM. To date, 11 studies have
examined the risk of ARM amongst exsmokers, reporting
an increased risk of developing ARM when compared to
never-smokers, but lower risk when compared to current
smokers [20, 32, 111–113, 115, 117, 118, 120, 121, 128].
Indeed, pooled data from the Beaver Dam Eye Study, the
Blue Mountains Eye Study, and the Rotterdam Eye Study
demonstrated cross-sectionally, and in their extended cohort
studies that exsmokers had only a slightly increased risk of
ARM when compared to nonsmokers, with even greater risk
reduction at extended followup [23, 26]. The Physicians’
Health Study evaluated the risk of ARM in exsmokers, taking
into account their previous intensity of smoking and the
timesincecessation.Subjectswhosmoked>20cigarettes/day
still appeared to have an increased risk of ARM when they
stopped smoking >20 years previously [117]. Exsmokers
who had smoked <20 cigarettes/day, regardless of when they
had stopped smoking, had a similar risk of ARM as did
nonsmokers [117].
The results of an association between cigarette smoking
and risk for ARM, however, are not entirely consistent, and
some studies have failed to identify any association, or have
demonstrated only a weak association between tobacco use
and ARM [144–146]. Of note, these latter studies should
be interpreted with full appreciation of their limitations,
including small sample size and the nonprospective nature
of the reports.
Finally, although the Beaver Dam Eye Study reported
a strong association between smoking and neovascular late
ARM at baseline, this association was weaker at the 5-year
and 10-year followup examination [20, 147]. However, this
latter ﬁnding may be attributable to a relatively smaller
number of cases at followup (only 56% of baseline subjects
were evaluated at the 10-year followup). Indeed, dropout
in cohort studies may cause bias towards a null, or even
ap r o t e c t i v e ,e ﬀect of smoking, if dropout occurred more
frequentlyamongsmokers,asheavytobaccouseisassociated
with increased morbidity and mortality. In fact, the eﬀect of
such bias is likely to increase with study longevity.
In summary, the current evidence is broadly consistent
across a range of populations and study designs. Depending
on the type of ARM in question (early, atrophic late ARM, or
neovascular late ARM), the risk of developing ARM is two or
three times amongst current smokers when compared with
never smokers. Three large epidemiologic studies carried
out on three diﬀerent continents, and the pooled data and
prospective arms of these studies, provide strong evidence
in support of the view that cigarette use is associated with
increased risk for ARM [23, 26].
3.2.3. Diabetes Mellitus. Diabetes mellitus is a known risk
factor for the development of atherosclerosis [96, 97]. In
many epidemiologic studies, self-reporting of diabetes or
treatmentofdiabeteswasusedtodeterminewhethersubjects
had this condition, whereas some studies included a random
blood glucose measurement. All of these studies have been
consistent in their failure to identify an association between
diabetes mellitus and prevalent or incident ARM. This
ﬁnding may appear to be inconsistent with the vascular
hypothesis for the pathogenesis of ARM. However, decreased
scleral rigidity has been reported in patients with diabetes
mellitus, and advocates of the vascular hypothesis for
ARM argue that this may have a protective eﬀect for this
condition, and, therefore, explain the lack of an association
between ARM and diabetes mellitus [101]. Other possible
reasons for the lack of an observed association between
diabetes mellitus and ARM include selective survival (due
to increased and premature mortality rates amongst diabetic
subjects), particularly in the context of longitudinal study
design. Furthermore, coexisting diabetic maculopathy may
lead to an ascertainment bias, related to diﬃculties in the
classiﬁcation of age-related maculopathy [148].
It is interesting to note that a recent publication on
glycaemic index (related to carbohydrate intake) and ARM
within the AREDS study concluded that a reduced glycaemic
index in nondiabetic individuals may be associated with
reduced risk for ARM [149]. This observation is important
because hyperglycaemia-mediated damage can occur below
the diabetic threshold.
3.2.4. Hypertension (Table 4). Hypertension is a known risk
factor for atherosclerosis [96, 97]. Furthermore, alterations
in choroidal blood ﬂow are known to occur in the presence
of hypertension, consistent with the view that hypertensionJournal of Ophthalmology 11
may be etiologically important for ARM [150–153]. How-
ever, the data from epidemiologic studies is not particularly
supportive ofthis hypothesis. Forthesestudies, subjectswere
deemed to be hypertensive if systolic blood pressure was
≥160mm Hg and/or diastolic blood pressure was ≥95mm
Hg. Pulse pressure was taken as the diﬀerence between
systolic and diastolic blood pressure. In many studies, a
history of antihypertensive medication was also recorded
for each subject. Data from case-control studies and some
population-based studies has shown a positive association
between hypertension and the prevalence of both early and
late ARM [98, 121, 123–126, 128, 154]. However, a large
number of population-based studies have failed to show any
signiﬁcant association between the prevalence of either stage
of ARM and hypertension [122, 155].
TheassociationbetweenhypertensionandincidentARM
has also been investigated, and most studies have failed
to identify any signiﬁcant relationship (Table 4). However,
prospective data from the Rotterdam study showed that
high systolic blood pressure and/or high pulse pressure was
associated with increased risk of all ARM subtypes [124].
The investigators also attempted to answer the question as to
whether hypertension is an independent risk factor for ARM
or only through its association with atherosclerosis. They
found that adjustment for measures of atherosclerosis did
not attenuate the observed association between hypertension
and ARM. These ﬁndings from the Rotterdam Study are
consistent with those of the Beaver Dam Eye Study, which
showed that an increase in systolic blood pressure between
baselineandtheﬁve-yearfollowupassessmentwasassociated
with an increased risk of incident neovascular AMD at the
10-year followup assessment [125, 126, 128]. Taken together,
these studies provide convincing evidence of a mild-to-
moderate association between hypertension and ARM. Of
note, there is no convincing epidemiologic data that shows a
reductioninriskforARMinsubjectstakingantihypertensive
agents [98].
Hypertensive small vessel disease may lead to focal
ischemic changes in the cerebral white matter [60]. The
association of white matter lesions in the brain and risk for
ARM,asdetectedbymagneticresonanceimaging(MRI),has
been investigated in population-based epidemiologic studies
[60]. In the Cardiovascular Health Study, MRI-detected
cerebral white matter changes were associated with risk of
early ARM [57], although this ﬁnding was not replicated in
the Atherosclerosis Risk in Communities Study [60].
Prolonged hypertension may be associated with changes
in the retinal vasculature, such as focal arteriolar narrowing,
arteriovenous nipping, as well as retinal arteriolar and venu-
lar narrowing [60, 156]. The 5-year and 10-year incidence
data from the Blue Mountains Eye Study demonstrates that
AV nipping and, to a lesser extent, focal arteriolar narrowing
are associated with an increased risk of developing late ARM,
thus providing indirect evidence that hypertension may be
related to the development of ARM [157, 158]. In contrast,
however, the Beijing Eye Study found that retinal vascular
abnormalities were not signiﬁcantly associated with either
the prevalence or incidence of early or late ARM [153].
Cross-sectional data from the Beaver Dam Eye Study did not
ﬁnd that smaller retinal arteriolar diameter was associated
with any ARM end-point, but was associated with incident
RPE depigmentation in the prospective arm of that study
(an observation also reported in the Atherosclerosis Risk in
Communities Study) [59, 157, 159]. Taken together, the data
from these cited studies fails to provide convincing evidence
that retinal arteriolar changes are related to risk for ARM. It
should be stated, however, that ocular changes secondary to
systemic hypertension that are associated with ARM, if any,
may well be choroidal rather than retinal in manifestation.
3.2.5. Plasma Lipids (Table 5). Serum lipids include choles-
terol and triglycerides, with cholesterol having multiple sub-
types, including low-density lipoprotein (LDL) cholesterol,
high-density lipoprotein (HDL) cholesterol, and very low
density lipoprotein (VLDL) [164]. Most epidemiologic stud-
ies investigating a possible association between serum lipids
and ARM have measured LDL cholesterol, HDL cholesterol,
and triglyceride. As stated, the progressive deposition of lipid
is central to the vascular hypothesis of ARM pathogenesis
and, therefore, a relationship between serum cholesterol and
ARM would be consistent with such a hypothesis [165, 166].
However, evidence for such an association from epi-
demiologic studies, to date, has been unimpressive, with
few reports of an association between hyperlipidaemia and
ARM. Nevertheless, high serum cholesterol was associated
with a 2.2-fold increased risk of neovascular ARM in
the Eye Disease Case-Control Study [119], and the cross-
sectional POLA study also reported an association between
the presence of soft drusen and high HDL cholesterol [122].
The prospective arm of the Rotterdam Eye Study reported
an increased risk of incident ARM in association with
high serum levels of HDL cholesterol, in a dose-dependent
manner [161].
However, most epidemiologic studies have failed to
detect an association between elevated serum lipid levels and
lateARM.Moreover,somestudieshaveshownthathighLDL
cholesterol and low HDL cholesterol were actually protective
for prevalent and incident ARM (Table 5), with the pooled
cross-sectional data from the Beaver Dam Eye Study, the
Blue Mountains Eye Study, and the Rotterdam Eye Study
reporting a nonsigniﬁcant reduction in risk for neovascular
and atrophic late ARM in association with increasing
cholesterol levels [23, 26, 167]. To explain these seemingly
contradictory ﬁndings, the investigators speculated that high
plasma cholesterol levels might lead to downregulation of
LDL receptors in the retinal pigment epithelium (RPE), with
a consequential protective eﬀect [23, 26, 167].
Epidemiologic studies and clinical trials have investi-
gated the relationship between cholesterol-lowering agents
(statins)andARM,butuntilrecently,noassociationbetween
theuseofthesemedicationsandtheincidenceorprogression
of ARM has been reported [125, 128, 160, 162, 167–169].
For example, prospective data from the 15-year followup
examination of the Beaver Dam Eye Study reported no
protective eﬀect with statin use, as assessed at the 10-year
examination, with respect to incident early or late ARM,
or with respect to progression to late ARM [18, 19, 170].
However, in the latest analysis of the Blue Mountains Eye12 Journal of Ophthalmology
Table 5: Studies investigating the relationship between cholesterol and risk for ARM.
Study No. of cases Measure of risk factor Type of ARM Odds ratio or relative
risk
95% conﬁdence
interval
Cross-Sectional Studies
Cardiovascular Health
Study [58]
2361
Serum total
cholesterol (per
10mg/dL increase)
ARM 0.95 0.91–0.98
National Health and
Nutrition Examination
Survey III [54]
8270
HDL cholesterol (per
mmol/L) Early ARM 1.30 0.99–1.71
Triglycerides (per
mmol/L) Soft drusen 0.88 0.79–0.99
Pathologies Oculaires Liees
aL ’ A g e[ 122]
2584 Cholesterol (per
mmol/L)
Soft drusen 1.07 0.97–1.17
Late ARM 0.97 0.71–1.31
HDL Cholesterol (per
mmol/L)
Blue Mountains Eye Study
[26]
3654 Cholesterol (per
10mg/dL)
Early ARM 0.95 0.84–1.09
Late ARM 1.08 0.92–1.27
Prospective studies
Beaver Dam Eye Study
[160]
3684
Serum Cholesterol
(per 10mg/dL
increase)
Geographic
Atrophy 1.29 1.05–1.58
Rotterdam Eye Study
[161, 162]
4776
Serum Cholesterol
(per 10mg/dL) Early ARM 0.96 0.84–1.09
HDL Cholesterol (per
mmol/L) Early ARM 1.38 0.92–1.79
Study, users of statin at baseline and at 5-year followup had
a 67% lower risk of developing indistinct soft drusen at the
10-year followup examination, and this diﬀered from the
prospective 5-year analysis of the same study where no such
association was reported [169].
Any attempt to reconcile the discrepancy of the results
between two similarly and well-designed prospective arms
of population-based studies must take account of the
diﬀerences in baseline ﬁndings between the Beaver Dam Eye
Study (BDES) and the Blue Mountain Eye Study (BMES).
For example, the ratio of statin users to nonusers was 1 :
14 and 1 : 4 in the BMES and the BDES, respectively
[18, 19, 169, 170]. Furthermore, the conversion to late ARM
was very low in both studies, and the BMES and the BDES
only had suﬃcient power (90% with an α-level of 0.5) to
detect signiﬁcant relative risk of 0.27 or 0.5, respectively
[18, 19, 169, 170].
Attempting to identify the causal or protective eﬀect
from data generated from a population-based study can be
complex, and warrants discussion. Cross-sectional studies,
in which the disease and exposure are measured at the
same time, inherently lack the ability to detect a true
temporal association. Cohort studies, such as the prospective
arms of the Beaver Dam Eye Study, the Blue Mountains
Eye Study, and the Rotterdam Eye Study, allow for such
inferences. However, and in the context of an infrequent
risk factor or an infrequent end-point (such as conversion
to neovascular ARM) prospective population-based studies
may have limited power to detect an association. Therefore,
the question remained unanswered is whether statin use
is protective for development, or progression, of ARM.
However, further followup of large cohorts with increasing
numberstakingstatinsshouldenhanceourunderstandingof
the protective role, if any, of statins for ARM. Nevertheless,
and even with more prolonged followup, diﬃculties arising
from unmeasured confounding, selective survival, and other
sources of bias will mean that the result of such studies
should be interpreted with appropriate caution.
3.2.6. Obesity (Table 6). Obesity is an established risk factor
for cardiovasculardisease, and many studies have shown that
obesity is a risk factor for hypertension and lipid abnormal-
ities, and, therefore, predisposes to atherosclerosis [96, 97].
Therefore, obesity may be a risk-factor for ARM only insofar
as it is an antecedent common to both cardiovascular disease
and ARM. Obese people may also have a decreased dietary
intake of important nutrients that are believed to protect
against ARM [171]. Alternatively, increased body fat may
impair antioxidant defense mechanisms within the retina.
For example, lutein and zeaxanthin are carotenoids found
in the retina, where they are known collectively as macular
pigment, and are believed to protect the central retina from
oxidative damage [172–175]. However, adipose tissue is a
major storage organ for these carotenoids, and it has been
shown that there is a relative lack of macular pigment in
obese subjects, thus attenuating the macula’s natural antiox-
idant defense mechanism [171, 176]. Furthermore, there
is a growing body of evidence implicating inﬂammatoryJournal of Ophthalmology 13
Table 6: Studies investigating the relationship between obesity and risk for ARM.
Study No. of cases Measure of risk factor Type of ARM Odds ratio or relative
risk
95% conﬁdence
interval
Cross-Sectional Studies
Beaver Dam Eye Study
[128]
4926 BMI
Neovascular
AMD 1.02 0.97–1.08
Geographic
atrophy 1.06 0.98–1.14
Blue Mountains Eye Study
[26] 3654 BMI > 30 Early ARM 1.78 1.19–2.68
BMI < 20 Early ARM 1.92 1.16–3.18
Pathologies Oculaires Liees
aL ’ A g e[ 163]
2584 BMI > 30 Late ARM 2.29 1.00–5.23
Retinal
pigmentary
abnormalities
1.54 1.05–2.26
Prospective Studies
Beaver Dam Eye Study
[18, 20, 125]
3583 BMI
Retinal
Pigmentary
Abnormalities
1.03 1.00–1.06
Pooled data: Beaver Dam
Eye Study/Blue Mountains
Eye Study/Rotterdam Study
[26]
9523 BMI > 30 Late ARM 0.87 0.51–1.47
mechanisms in the pathogenesis of ARM, and such processes
arealsolinkedwithobesity(discussedinwhatfollows)[177].
Body mass index (BMI) is deﬁned as the body weight
in kilograms divided by the height in meters squared,
and is the most commonly used measure of obesity in
epidemiologic studies [177–179]. Individuals with a BMI
> 30 are categorized as obese. In 2003, evidence from a
large cohort study demonstrated that a higher BMI was
signiﬁcantly associated with risk for progression from early-
to-late ARM [177–179].
Evidence to date from other studies is less convincing
(Table 6). In the cross-sectional arm of the Beaver Dam
Eye Study, BMI was a signiﬁcant risk factor for prevalent
pigmentary abnormalities in women, but not for prevalent
late ARM [180]. The prospective arm of the Beaver Dam
Eye Study also showed that, at ﬁve years, incident retinal
pigmentary changes (but not other ARM end-points) were
more common in obese subjects than in nonobese subjects
[181].
In the cross-sectional POLA study, participants with a
BMI > 30 showed a two-fold increased risk of late ARM,
when compared to subjects with a BMI < 25, and it was also
observed that participants with a BMI > 30 had an increased
risk of early ARM in the form of pigmentary changes at the
macula [163].
In the cross-sectional arm of the Blue Mountains Eye
Study, a high BMI and a low BMI were both associated with
an increased risk of prevalent early ARM [182]. However, it
should be noted that pooled data from the prospective arms
of the Beaver Dam Eye Study, the Blue Mountains Eye Study,
and the Rotterdam Study failed to detect an association
between increased BMI and incident ARM [23, 26].
Two recent, nonpopulation-based, prospective studies
have reported a two-fold increased risk of incident ARM in
obese subjects. The Physicians’ Health Study, a prospective
study of male physicians in USA, reported a two-fold
increased incidence of early ARM amongst obese subjects
[117].However,thissamestudyalsoreportedthattheleanest
men (BMI < 22) were also at increased risk of early ARM,
independent of other potential confounding variables, thus,
suggesting a J-shaped association of BMI and risk for ARM.
However, the prospective Hisayama study failed to detect
such any association between BMI and ARM [50, 51].
In conclusion, conclusive evidence that BMI represent
risk for ARM is still lacking. However, there appears to be a
growing body of evidence in support of the view that obesity
is an important determinant for the development and/or
progression of ARM.
3.2.7. Physical Inactivity and Inﬂammation. Obesity may
b eam a r k e ro fl a c ko fp h y s i c a la c t i v i t y ,a n ds u c hal a c k
of physical activity is associated with increased risk of
several factors that predispose to cardiovascular disease,
including hypertension, weight, and lipid proﬁle [107].
Indeed, engaging in regular physical activity reduces the risk
of developing cardiovascular disease [183]. Following acute
exercise, there is a transient increase in the circulating levels
of anti-inﬂammatory cytokines but with more prolonged
exercise, a reduction in proinﬂammatory cytokines has been
demonstrated [184]. Limited studies in humans and more
comprehensive assessments in animals have conﬁrmed the
athero-protective eﬀect of exercise [185, 186]. The Beaver
Dam Eye Study prospectively investigated whether physical
activity was related to the incidence of ARM, and found14 Journal of Ophthalmology
that after controlling for potentially confounding variables,
people with an active lifestyle were at reduced risk of
developing neovascular late ARM, when compared with
people with more sedentary lifestyles [187].
3.2.8. Female Sex Hormones (Table 7). There is a growing
debate amongst epidemiologists about the role of female sex
hormones in the etiopathogenesis of cardiovascular disease.
The observation that the risk of cardiovascular disease
is lower amongst women than amongst men before the
menopause, but rises in postmenopausal women, is well
documented. Indeed, observational studies have reported
thathormonereplacementtherapy,intheformofexogenous
estrogen, is protective against cardiovascular disease [191,
197–199].
A number of mechanisms have been put forward to
explain the putative protective eﬀect of female sex hormones
for cardiovascular disease [200]. First, estrogen may lead
to favorable alterations in serum lipids, ﬁbrinogen, or
plasminogen levels, and may exert antioxidant properties
[200]. Furthermore, changes in BMI and blood pressure are
also observed following the menopause, and such changes
may be etiologically important for ARM [191, 197, 198].
However, results from recent randomized controlled
studies,including the HeartandEstrogen/Progestin Replace-
ment Study (HERS) [201] and the Womens’ HealthInitiative
(WHI) [202], suggest a more complex relationship between
hormone replacement therapy and cardiovascular disease,
with results which diﬀer from those of the observational
studies cited earlier (which are based on the time from
menopause to initiation of hormone replacement therapy).
Indeed, the HERS, and subsequently the estrogen/progestin
arm of WHI, suggested that HRT may be associated with an
increased risk for cardiovascular in postmenopausal women.
However, it must be stated that these results have not
been conﬁrmed by the more recent report of the WHI on
e s t r o g e no n l y ,w h e r eap r o t e c t i v ee ﬀect of this hormone on
cardiovascular endpoints in young postmenopausal women
was demonstrated [203]. It appears, therefore, that time to
initiation of HRT, and the type of therapy, may be important
when investigating the possible role of female sex hormones
in cardiovascular disease, and possibly also in ARM [201,
202].
Epidemiologic studies have used a number of ways
to measure exposure to estrogen (Table 7). Exposure to
endogenous estrogen is related to the age at menarche, age
at menopause, and the number of pregnancies. Exposure
to exogenous estrogen is related to the use of hormone
replacement therapy and to the use of oral contraceptives.
The cross-sectional arm of the Beaver Dam Eye Study
found that high parity (i.e., decreased exposure to endoge-
nous estrogen) was associated with an increased prevalence
of early ARM [180, 181]. The same study also found that
HRT (exogenous estrogen) usage was associated with a
decreased risk of late ARM [180, 181]. The cross-sectional
arm of the Blue Mountains Eye Study found that increas-
ing number of years from menarche to menopause (i.e.,
increased endogenous estrogen exposure) was associated
with a lower prevalence of early ARM [180, 181, 188].
The cross-sectional Los Angeles Latino Eye Study reported
that exogenous estrogen had a protective eﬀect against the
development of early ARM [114]. In contrast with the
earlier ﬁndings, the cross-sectional data from the POLA
Study [189], Salisbury Eye Evaluation Project [190], and the
Aravind Comprehensive Eye Survey [191] failed to identify
any signiﬁcant protective eﬀect associated with exposure to
endogenous estrogen.
Incidence data from prospective studies is similarly
unconvincing. Five-year incident data from the Beaver Dam
Eye Study provided little evidenceof any association between
exposure to estrogen and incident ARM [181]. Interestingly,
the Rotterdam Study found that increased number of years
from menarche to menopause (i.e., increased exposure
to endogenous estrogen) was directly related to incident
geographic atrophy [192]. However, when this data was
pooledwithﬁndingsfromtheBeaverDamEyeStudyandthe
Blue Mountains Eye Study, no overall association between
estrogen exposure and incident ARM could be reported
[23, 26].
In summary, reports of studies designed to investigate
an association between exposure to estrogen (whether
exogenous or endogenous) and ARM are inconsistent.
Longitudinal analyses of prospective cohorts are required
to enhance our understanding of the association, if any,
betweenestrogenandriskforARM.Well-designed,random-
ized controlled studies are needed to investigate the putative
beneﬁcial eﬀect of HRT on incidence and/or progression of
ARM.
3.2.9. Other. A number of emerging risk factors for
atherosclerosis have recently been identiﬁed. These “novel”
riskfactorsincludelipid-relatedfactors,inﬂammatorymark-
ers, and infectious agents. [143, 154, 204]. Of note, some of
these risk factors are of interest to researchers investigating
risk for ARM in a way that is beyond the risk that
these variables represent for cardiovascular disease (e.g.,
inﬂammatory markers).
Apolipoproteins and lipoproteins are essential in the
transport of cholesterol and lipids. Apolipoprotein E has
three common alleles (2, 3, 4), which inﬂuence total
and LDL cholesterol levels. The association between the
apolipoprotein E gene and ARM has been discussed earlier
in this review.
Inﬂammatory markers that have been implicated as
risk factors for cardiovascular disease include C-reactive
protein, interleukins, serum amyloid A, vascular and cellular
adhesion molecules, and white blood cell count [205]. Many
of these markers have been investigated for an association
with ARM in population-based studies, and the ﬁndings are
presentedelsewhereinthisreview(reportedinwhatfollows).
Homocysteine is an amino acid, which is formed as a
by-product of the metabolism of the essential amino acid
methionine [154]. Elevated levels of homocysteine are asso-
ciatedwithanincreasedriskofcardiovasculardisease.Folate,
cobalamin (vitamin B12), and pyridoxine (vitamin B6) are
involved in the metabolism of homocysteine as cofactors,
and low levels of these vitamins may lead to high levels of
homocysteine.However,andwithrespecttoARM,datafromJournal of Ophthalmology 15
Table 7: Studies investigating the relationship between female sex hormones and risk for ARM.
Study No. of cases Measure of risk factor Type of ARM Odds ratio or relative
risk
95% conﬁdence
interval
Cross-Sectional Studies
Beaver Dam Eye Study
[180]
4926
Number of
pregnancies Early ARM 0.95 0.92–1.01
Hormone
replacement therapy
usage
Late ARM 0.94 0.63–1.39
Blue Mountains Eye Study
[24, 188]
3654 Years from menarche
to menopause Early ARM 0.97 0.95–0.99
Los Angeles Latino Eye
Study [114]
5875
Use of oral
contraceptive pills Early ARM 0.5 0.4–0.8
Use of hormone
replacement therapy Early ARM 0.8 0.6–1.2
Pathologies Oculaires Liees
aL ’ A g e[ 189]
2584 Hormone
replacement therapy Late ARM N/A N/A
Salisbury Eye Evaluation
Project [190]
1458
Current use of
hormone replacement
therapy
Early ARM 0,7 0.3–1.5
Late ARM 0.6 0.1–2.9
Aravind Comprehensive
Eye Survey [191]
5539
Age at menarche 14+ ARM 2.3 1.2–4.7
Age at menopause
<45 years ARM 1.5 0.3–8.1
Endogenous estrogen
exposure <30 years ARM 2.2 0.4–12.0
Prospective Studies
Beaver Dam Eye Study
[181]
3684
Hormone
replacement therapy
(3+ years)
Early ARM 0.98 0.56–1.73
Late ARM 1.30 0.36–5.21
Rotterdam Study
[23, 26, 192]
4616
Early menopause
following
oophorectomy
ARM 3.8 1.1–12.6
Pooled data: Beaver Dam
Eye Study/Blue Mountains
Eye Study/Rotterdam Study
[23, 26]
9523
Time from menarche
to menopause per
year
Late ARM 0.99 0.95–1.03
Hormone
replacement therapy Late ARM 1.00 0.40–2.45
population-based studies is limited. In the National Health
and Nutrition Examination Survey III, analysis of cross-
sectional data revealed that total serum homocysteine, red
blood cell folate, and serum cyanocobalamin were unrelated
to ARM [55]. In 2007, the Blue Mountains Eye Study found
that high levels of serum homocysteine and low levels of
serum vitamin B12 were independently associated with an
increased risk of late ARM [206].
Infectious agents, such as cytomegalovirus, Chlamydia
pneumoniae,a n dHelicobacter pylori have been putatively
linked to risk for cardiovascular disease [207–209]. A
single study demonstrated a signiﬁcant association between
high cytomegalovirus IgG titers and neovascular AMD,
but no association between Helicobacter pylori IgG titers
and ARM [209]. The association between ARM and either
cytomegalovirus or Helicobacter pylori has not been exam-
ined, thus far, in population-based epidemiologic studies.
Research has been carried out on the relationship between
Chlamydia pneumoniae and ARM, although the ﬁndings
have been inconsistent [207, 210]. The Cardiovascular and
Age-Related Maculopathy (CHARM) Study demonstrated
that participants with high titers of antibodies to Chlamydia
pneumoniae exhibited an increased risk of ARM progression
[58].
4. Indicatorsof Inﬂammation (Table 8)
It has also been postulated that ARM may represent an
ocular manifestation of chronic inﬂammatory processes
[211]. This hypothesis has recently been given fresh impetus
by the discovery that patients with a certain variant of
the complement factor H gene (Y402H) are at signiﬁcantly
increased risk of developing ARM [65].
4.1. Hypothesis/Rationale. The inﬂammatory model pro-
poses that some form of tissue injury leads to a localized16 Journal of Ophthalmology
Table 8: Studies investigating the relationship between indicators of inﬂammation and risk for ARM.
Study No. of cases Measure of risk factor Type of ARM Odds ratio or relative
risk
95% conﬁdence
interval
Cross-Sectional Studies
Atherosclerosis Risk in
Communities Study
11264 White blood cell
count
Early and late
ARM N/A N/A
National Health and
Nutrition Examination
Survey III [26, 54]
8270 Serum albumin Early ARM 0.97 0.95–1.00
Cardiovascular Health
Study [193]
2361 Serum albumin Early ARM 0.59 0.39–0.92
Plasma Fibrinogen Early ARM N/A N/A
Cardiovascular Health
Study [193] 2755 C-reactive protein Early and Late
ARM 1.24
0.87–1.78 (4th
Quartile)
Beaver Dam Eye Study
[194, 195]
2764
Gout Early ARM 0.69 0.41–1.16
Late ARM 2.18 1.06–4.47
Emphysema Early ARM 1.11 0.49–2.51
Late ARM 2.55 0.74–8.81
Beaver Dam Eye Study
[194, 195]
3684
NSAIDs Early ARM 1.04 0.78–1.38
Aspirin Early ARM 1.08 0.79–1.48
Oral steroids Early ARM 0.80 0.28–2.28
Blue Mountains Eye Study
[196]
2313 Steroids or NSAIDs Early ARM 1.2 0.8–1.6
Late ARM 0.9 0.4–1.9
Beaver Dam Eye Study
[194, 195]
2764
White blood cell
count
Early ARM 1.03 0.98–1.10
Late ARM 0.99 0.86–1.14
Serum albumin Early ARM 0.91 0.64–1.29
Late ARM 0.52 0.24–1.14
inﬂammatory response in the retina, involving human
leukocyte antigen (HLA) and the complement system [65,
106, 211]. This inﬂammatory response leads to drusen
formation and alteration of the extracellular matrix, which,
in turn, leads to altered RPE-choriocapillaris behavior
and, ultimately, to choroidal neovascularization and other
c h a n g e ss e e ni nl a t eA R M[ 106, 211, 212]. Indeed, a number
of in vitro studies provide evidence in support of this
view. For example, the cellular and molecular constituents
of drusen have been analyzed in detail [102, 103, 106,
213], and have been shown to contain proteins associated
withimmune-mediated processes and inﬂammation, suchas
complement components, immunoglobulins, and anaphy-
latoxins. Furthermore, histological studies have consistently
demonstrated chronic inﬂammatory cells within retinas
aﬄicted with ARM. It is believed that these inﬂammatory
cells may damage tissue by release of proteolytic enzymes,
oxidants, and toxic oxygen compounds.
The human immune system contains both innate and
adaptive components [102]. The innate immune system
includes complement, macrophages, and leukocytes. The
complement system is activated by foreign proteins or
damaged cells leading to their destruction by host defenses.
C3b is a component of complement that is deposited on
both host and foreign cells [214]. Complement factor H
(CFH) binds and inactivates C3b deposited on intact host
cells, thereby preventing their destruction, and, thus, playing
a critical role in the regulation of this inﬂammatory process.
Recent genome-wide linkage analyses have identiﬁed a gene
locus for ARM on Chromosome 1, and case-control studies
wentfurther,identifyingCFHastheresponsiblegene[64,65,
215, 216]. This gene has many polymorphisms that relate to
ARM. Of these, the Y402H variant, which is located within a
binding site for C-Reactive Protein (CRP), has the strongest
association with ARM [64, 65, 215, 216]. This ﬁnding
enhances our current understanding of ARM pathogenesis,
and is supportive of the view that inﬂammatory changes are
etiologically important for this condition.
4.2. Epidemiologic Studies. A number of case-control and
cohort studies have provided evidence in support of the
view that inﬂammatory changes are etiologically important
for ARM. Until recently, however, the evidence from large
population-based epidemiological studies has been less con-
sistent in this regard (Table 8) .T h e s es t u d i e sh a v et e n d e dt o
lookatassociationsbetweenARMandsystemicdiseaseswith
inﬂammatory components, as well as markers of systemic
inﬂammation. In 2003, the Beaver Dam Eye Study published
data that revealed a modest association between the 10-year
incidence of ARM and gout and pulmonary emphysema,
independent of cigarette smoking and other risk factors
[194]. Of note, however, aspirin and other nonsteroidal anti-
inﬂammatory agents have not been found to be associated
with risk reduction for ARM [52, 53].Journal of Ophthalmology 17
The Beaver Dam Eye Study demonstrated an association
between the 10-year incidence of ARM and high white blood
cell count and with low serum albumin [20, 128, 194, 195],
but this ﬁnding has not been consistent.
Plasma ﬁbrinogen is a well-established marker of sys-
temic inﬂammation, and elevated ﬁbrinogen levels are seen
in association with arthritis, diabetes mellitus, and certain
cardiovascular risk factors [193]. The Cardiovascular Health
Study failed to detect an association between serum ﬁbrino-
gen levels and the prevalence of early ARM [193]. However,
the Blue Mountains Eye Study demonstrated an association
between elevated ﬁbrinogen levels and the prevalence of late
ARM [217].
In 2004, Seddon et al. demonstrated raised CRP levels
in association with intermediate and advanced ARM, when
compared with a control proband [218]. The prospective
followup of CRP levels with respect to ARM, published in
2005 (by the same authors) demonstrated that both CRP
and IL-6 were signiﬁcantly and independently related to pro-
gression of ARM, after adjusting for potential confounders
[219]. Indeed, subjects in the highest quartile of CRP had
a two-fold greater risk of ARM progression than subjects in
the lowest quartile, thus corroborating the conclusions of
the previous cross-sectional study [218, 219]. However, an
association between CRP and ARM was not observed in the
cross-sectional data from either the Cardiovascular Health
Study or the Beaver Dam Eye Study [57, 193].
More recent epidemiologic studies have been able to
investigatetheroleofcomplementfactorHY402Hpolymor-
phism with respect to ARM. The Rotterdam Study tested for
the CFH Y402H polymorphism in a total of 5681 individuals
(11363 alleles), and identiﬁed this polymorphism in 36.2%
[220, 221]. It was reported that the risk of developing late
ARM by age 95 years was 48.3% and 42.6% for homozygotes
and heterozygotes, respectively, with this polymorphism,
and this compares with only 21.9% for noncarriers. In
that study, erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP) levels were also measured, and it was
found that both of these markers of systemic inﬂammation
were associated with increased risk of ARM in carriers of
the CFH Y402H polymorphism, but that neither of these
markers represented risk for developing ARM in noncarriers
[220, 221]. This novel and interesting ﬁnding may explain
the inconsistent results with respect to the relationship
between these markers of systemic inﬂammation and ARM
in previous studies. Indeed, it was this potential source
of confounding that prompted the authors to, therefore,
examine the CRP gene in relation to ARM, and it was
foundthatCRPhaplotypes thatincreaseserumlevelsofCRP
are associated with signiﬁcantly enhanced eﬀects of CFH
Y402H polymorphism [220]. Also, and interestingly, the
same investigators found that smoking cigarettes increased
the risk of early and late ARM by a factor of 3.3, and that
homozygosity for the CFH Y402H polymorphism increased
the risk by a factor of 12.5; however, the combination of
both these risk factors resulted in an increased cumulative
risk of ARM by a factor of 34 [72, 221]. In other words,
and because tobacco use has been shown to activate the
complement system, smoking cigarettes may accentuate and
facilitate the deleterious eﬀects of inﬂammatory changes
with respect to ARM in an individual with the CFH Y402H
polymorphism. This represents an example of an interaction
between genetic background and environment to promote a
pathologic process [72, 221].
Other, and more novel, markers for inﬂammation have
also been examined with respect to ARM. In two samples of
participants from the Beaver Dam Eye Study, no association
was found between serum amyloid A, interleukin-6, or
tumor necrosis factor and the prevalence or incidence
of ARM [194, 195]. This study also examined mark-
ers of endothelial cell dysfunction (intercellular adhesion
molecule-1(ICAM-1)andE-selectin),andfailedtodetectan
association between either of these parameters and the risk
for ARM.
5. Indicatorsof OxidativeStress
Animals release energy from dietary carbohydrates, proteins,
and lipids by cellular oxidative processes. These processes
include the tricarboxylic acid (TCA) cycle and oxidative
phosphorylation [173, 222]. Cellular damage arising from
oxidative processes appears to play a role in physiological
and pathological aging. The free radical theory of aging
proposesthatagingandage-relateddisordersaretheresultof
cumulative damage arising from reactions involving reactive
oxygen intermediates [173, 222, 223].
Reactive oxygen intermediates (ROIs) is a term used to
describefreeradicals,hydrogenperoxide,andsingletoxygen.
These molecules are produced in the cell as by-products
of oxidative processes, and result in cytotoxic oxidative
chain reactions. An increase in the production of ROIs
is seen in association with aging, and in association with
inﬂammation, cigarette smoking, and irradiation [173, 222,
223].
Cells have multiple mechanisms to protect against the
eﬀects of oxygen toxicity [173]. These include DNA repair
mechanisms and the separation of ROIs from cellular
components that are susceptible to oxidative damage. Also,
several enzymes have antioxidant properties, and these
include glutathione peroxidase, catalase, and superoxide
dismutase [224, 225]. Numerous vitamins also have antioxi-
dant properties, reacting directly and nonenzymatically with
ROIs, yielding harmless products [226].
5.1. Hypothesis/Rationale. Oxidative processes occur in the
retina, and it is postulated that they are etiologically
important in the pathogenesis of ARM [173]. For a number
of reasons, the retina represents an ideal environment for
the generation of, and damage by, ROIs [173, 226, 227].
First, the retina has a much greater consumption of oxygen
than other tissues. Second, the retina is subjected to a
lifetime of cumulative light exposure, and thus high levels
of cumulative irradiation [173, 226, 227]. Third, the outer
segments of photoreceptors are rich in polyunsaturated
fatty acids and these molecules are especially susceptible
to oxidative damage [224, 225]. Fourth, the neurosensory
retina and RPE contain an abundance of photosensitizers,
which generate oxidative chemical reactions in response to18 Journal of Ophthalmology
light [173]. Finally, phagocytosis by the RPE results in the
production of hydrogen peroxide [228].
In other words, it appears that oxidative damage of
the retina may represent a common pathway, which is
important for the development of ARM, and which is
not inconsistent with other hypothesized etiologies and/or
risk-factors for ARM, including cumulative light damage,
inﬂammatory processes, hemodynamic abnormalities, and
genetic predisposition.
5.2. Epidemiologic Studies. Although much of the work on
oxidative processes in relation to ARM has been laboratory-
based, there is now a growing number of epidemiologic
studies investigating the role, if any, of oxidative processes in
the pathogenesis of ARM.
Such epidemiologic studies tend to investigate parallels
between the prevalence (and/or incidence) of ARM and
antioxidant or pro-oxidant status [229].
5.2.1. Antioxidant Status. Antioxidant status is assessed by
evaluating defense mechanisms against oxidative stress. Such
measuresmayincludedietaryintakeofrelevantantioxidants,
or serum or tissue (e.g., macular pigment optical density)
levels of such antioxidants [225, 229–231].
(a) Vitamin C (Table 9). Vitamin C (ascorbic acid) is thou-
ght to be essential for protection against disease processes
caused by oxidative stress. It is the most eﬀective aque-
ous phase antioxidant in human blood [232]. Foods rich
in vitamin C include citrus fruits/juices, green peppers,
broccoli, and potatoes [232]. In 1988, cross-sectional data
from the National Health and Nutrition Examination Survey
(NHANES) I reported that the consumption of foods rich
in vitamin C was negatively associated with the prevalence
of ARM (Table 8)[ 54]. However, after adjusting for demo-
graphic and medical factors, this association was no longer
present [54].
The Age-Related Eye Disease Study (AREDS) provided
evidence that, in addition to zinc, antioxidant supplementa-
tion may slow ARM progression in relatively advanced early
ARM cases [121, 175]. In that study, trial participants who
received a daily high-dose supplement of vitamins C and
E and B-carotene had an approximately 25% reduced risk
of progression from relatively advanced early cases of ARM
to late stage disease (OR 0.72). Vitamin C in isolation was
not examined. Furthermore, this study did not address the
question of primary prevention in those with no signs of
ARM.
Cross-sectional data from the Beaver Dam Eye Study
also showed that a high dietary intake of vitamin C was
negatively associated with early ARM, but this ﬁnding
was not statistically signiﬁcant [229, 237]. In 1999, cross-
sectional data from the Blue Mountains Eye Study reported
noassociation betweenvitaminCand theprevalenceofearly
or late ARM [229, 233], and the investigators subsequently
reported, in prospective arms of these studies, that high
intake of vitamin C from diet and/or supplements was
neither associated with an increased or decreased risk of
incident early ARM [226, 229]. Finally, in the prospective
arm of the Rotterdam Eye Study, it was shown that an
above-median intake of vitamin C, in combination with
vitamin E, beta-carotene, and zinc, was associated with a
signiﬁcant 35% reduction in risk for incident ARM [229,
235].However,itshouldbenotedthatsuchaprotectiveeﬀect
wasnot detected with dietary intake of vitamin C in isolation
of the other nutrients mentioned earlier, consistent with
the view that antioxidants work synergistically and that a
broad spectrum of antioxidant intake is important to protect
against oxidative stress.
Serum levels of vitamin C have also been examined
in relation to risk for ARM. Cross-sectional data from
the Baltimore Longitudinal Study of Aging reported a
nonsigniﬁcant protective eﬀect associated with high levels of
plasma vitamin C, but this ﬁnding was not replicated in the
POLA study [29, 229, 236].
In summary the relationship between vitamin C and
ARM remains unclear. The majority of studies have failed to
demonstrate a clear association between either dietary intake
or serum levels of vitamin C and ARM (OR 0.6–1.15).
(b) Vitamin E (Table 10). Vitamin E is the major antioxidant
of cellular membranes [229, 230, 238]. It exists in four
common forms, including α-tocopherol, β-tocopherol, γ-
tocopherol, and δ-tocopherol. α-Tocopherol is predominant
in human retina and plasma [238, 239], and, within the
retina, is located in the rod outer segments and in the RPE,
and the concentrations within these tissues are very sensitive
to dietary intake of this vitamin [238, 240, 241]. Food rich
in vitamin E includes whole grains, vegetable oil, eggs, and
nuts [238]. Dietary intake of vitamin E is diﬃcult to estimate
because the long-term consumption of oils is diﬃcult to
determine by questionnaire.
The Beaver Dam Eye Study showed that the prevalence
of early ARM was lower for people in the highest versus
lowest quintiles for dietary intake of vitamin E (Table 9)
[237], although this association did not reach statistical
signiﬁcance. TheBeaver DamEyeStudy subsequentlylooked
at the incidence data, and found that high dietary intake
of vitamin E was associated with a decreased incidence of
large drusen but that, overall, it was not protective for early
ARM [229]. More recently, the Rotterdam Study published
strong evidence that a high dietary intake of vitamin E was
associated with a lower risk of incident ARM [229, 235]
and reported that exclusion of supplement users did not
attenuate their ﬁndings.
Less evidence has been published on the association, if
any, between serum levels of vitamin E and ARM. Vitamin
E is transported by lipoproteins, and it is increasingly rec-
ognized that plasma α-tocopherol levels should be expressed
in terms of its concentration within these lipoproteins [229,
235]. A nested case-control study within the Beaver Dam
Eye Study showed no statistically signiﬁcant association
between average serum levels of vitamin E and ARM [229].
Examination of samples from the Blue Mountains Eye Study
also failed to detect an association between serum vitamin E
and ARM [229, 242]. The POLA study carried out the most
comprehensive examination of the link between vitamin
Ea n dA R M[ 29, 229, 236], and the investigators foundJournal of Ophthalmology 19
Table 9: Studies investigating the relationship between vitamin C and risk for ARM.
Study No. of cases Measure of risk factor Type of ARM Odds ratio or relative
risk
95% conﬁdence
interval
Cross-Sectional Studies
National Health and
Nutrition Examination
Survey I [54]
3082 Dietary intake Early and late
ARM 1.15 0.79–1.66
Blue Mountains Eye Study
[233] 2900 Dietary Intake Early ARM 0.9 0.5–1.4
Late ARM 1.3 0.5–3.4
Prospective Studies
Beaver Dam Eye Study
[234] 1968 Dietary intake Early ARM 0.8 0.5–1.2
Late ARM 0.6 0.2–2.0
Blue Mountains Eye Study
[226, 233]
1989 Dietary intake Early ARM 2.3 1.3–4.0
Rotterdam Study [235] 4170
Dietary intake of
vitamin C in
combination with
vitamin E, β-carotene
and zinc
Early and late
ARM 0.65 (Hazard Ratio) 0.46–0.92
Baltimore Longitudinal
Study of Aging [231]
678 Fasting plasma level Early and late
ARM 0.55 0.28–1.08
Pathologies Oculaires Liees
aL ’ A g e[ 29, 236]
1791 Fasting plasma level Late ARM 0.89 0.32–2.5
Table 10: Studies investigating the relationship between vitamin E and risk for ARM.
Study No. of cases Measure of risk factor Type of ARM Odds ratio or relative
risk
95% conﬁdence
interval
Cross-Sectional Studies
Pathologies Oculaires Liees
AL ’ A g e[ 29, 236]
2157 Lipid-standardized
plasma level Late ARM 0.18 0.05–0.07
Prospective Studies
Beaver Dam Eye Study
[237]
1968 Dietary intake 0.7 0.5–1.1
1.5
0.5–4.6
Beaver Dam Eye Study
[237]
1709
Dietary intake in the
past Large drusen 0.4 0.2–0.9
Dietary intake at
baseline Large drusen 0.8 0.4–1.7
Rotterdam Study [235] 4170 Dietary intake Early and late
ARM 0.92 (Hazard Ratio) 0.84–1.0
that plasma α-tocopherol levels showed a weak negative
association with the prevalence of late ARM. Furthermore,
the POLA investigators were the ﬁrst to assess the lipid-
standardized levels of α-tocopherol, and these measures also
showed a signiﬁcant negative association with late ARM [29,
229, 236]. Similarly, cross-sectional data from the Baltimore
Longitudinal study of Aging demonstrated a signiﬁcantly
lower risk of ARM in subjects with the highest versus
lowest plasma levels of vitamin E [231]. However, vitamin
E intervention studies have failed to detect a protective
eﬀect of vitamin E supplementation on the development or
progression of ARM [229, 243, 244].
Therefore, the body of evidence that vitamin E is
protective for ARM remains inconsistent.
(c) Vitamin A (Table 11). Vitamin A (retinol) is vital for
the regeneration of rhodopsin in the retina, and is therefore
essential for vision [54, 229] .T h e r ei ss o m ee v i d e n c et o
suggest that retinol has antioxidant activity in photoreceptor
cells, and that it is also involved in the repair of cells
that have been oxidatively damaged. NHANES I provided
evidence that dietary intake of foods rich in vitamin A were
negatively associated with the prevalence of ARM, even after
adjustment for demographic and medical factors (Table 10)20 Journal of Ophthalmology
Table 11: Studies investigating the relationship between vitamin A and risk for ARM.
Study No. of cases Measure of risk factor Type of ARM Odds ratio or relative
risk
95% conﬁdence
interval
Cross-Sectional Studies
National Health and
Nutrition Examination
Survey I [54]
3082 Dietary intake Early and late
ARM 0.74 0.50–1.10
Pathologies Oculaires Liees
aL ’ A g e[ 29, 236]
2157 Plasma Level Late ARM 0.6 0.17–2.12
Prospective Studies
Blue Mountains Eye Study
[233] 2900 Dietary intake Early ARM 1.2 0.7–2.0
Late ARM 1.2 0.5–3.3
Blue Mountains Eye Study
[226, 233]
1989 Dietary intake Early ARM 0.9 0.6–1.6
[54, 229], but this ﬁnding has not been corroborated by
other large population-based studies [233, 236]. The Blue
Mountains Eye Study failed to detect an association between
dietary intake of vitamin A and either the prevalence or
incidence of ARM [229, 233]. Furthermore, the POLA study
also failed to detect an association between plasma retinol
and ARM [29, 229, 236].
(d) Carotenoids (Table 12). Carotenoids are naturally occur-
ring pigments [140]. Some carotenoids can be converted
to vitamin A and are, therefore, classed as provitamin A
cartenoids. Carotenoids also have antioxidant properties,
and act synergistically with other antioxidants [139, 140,
173, 247]. Thirty four carotenoids have been identiﬁed in
serum and, of these, only lutein, zeaxanthin, and meso-
zeaxanthin are found in the human retina, where they are
collectively referred to as macular pigment [139, 140, 173,
247–249]. Macular pigment is entirely of dietary origin, and
can be augmented with appropriate dietary modiﬁcation
and/or supplementation [250]. As well as direct antioxidant
eﬀects, macular pigment is also believed to limit retinal
oxidative damage by ﬁltering out blue light [251]. The
macular carotenoids are found in high concentrations in
certain foods, such as carrots, kale, and spinach [250].
In the Beaver Dam Eye Study, dietary intake of
carotenoids was unrelated to the prevalence of early or
late ARM (Table 11)[ 252]. However, further work from
the Beaver Dam Eye Study showed an inverse association
between dietary intake of pro-vitamin A carotenoids and the
incidence of large drusen [252]. Of note, the Blue Mountains
Eye Study failed to detect an association between dietary
intake of α and β-carotenes and the prevalence or incidence
of ARM [233, 242]. More recently, the Rotterdam Study
showed that a high intake of beta-carotene, in combination
with vitamin C, vitamin E, and zinc, was associated with a
signiﬁcantly reduced risk of incident ARM [235]. However,
in that study, the associations between ARM and either beta-
carotene, lutein, or zeaxanthin in isolation were not found to
be signiﬁcant.
However, the macular carotenoids are likely to be more
relevant to risk for ARM than B carotene, especially since
B-carotene is not found in the human neurosensory retina.
Foods that are rich in lutein and zeaxanthin include leafy
green vegetables, corn, green peppers, and egg yolks [140].
Data from the NHANES III showed that in younger age
groups, higher levels of lutein and zeaxanthin in the diet
wererelatedtolowerriskofretinalpigmentaryabnormalities
[245]. Overall in this study, however, no convincing evidence
of an inverse relationship between dietary intake of lutein
and zeaxanthin and the risk of ARM was detected. Nev-
ertheless, the AREDS study provided evidence that dietary
intake of lutein and zeaxanthin was inversely associated with
neovascular ARM (OR 0.65), geographical atrophic changes
(OR 0.45) and large or extensive intermediate drusen (OR
0.73) [121, 175].
Serum levels of α-a n dβ-carotene, γ-cryptoxanthin,
and lycopene, as measured in subsamples of the Beaver
Dam Eye Study and Blue Mountains Eye Study, failed to
demonstrate any consistent associations with ARM [229].
Of note, in 2001, the NHANES III reported no relationship
between serum lutein (or zeaxanthin) and any form of ARM
[229, 245]. However, until recently, lutein and zeaxanthin
in the plasma could not be easily separated. In 2006, the
POLA study demonstrated that high plasma zeaxanthin was
associated with a markedly reduced risk of ARM [229, 246].
High plasma lutein, total lutein, and zeaxanthin in the
serum were also associated with a reduced risk of ARM. The
investigators hypothesized that the stronger association of
plasma zeaxanthin (when compared with lutein) with ARM
may berelated to thefactthatthecentralretina preferentially
accumulates zeaxanthin, and that zeaxanthin appears to be
a better photoprotector during prolonged exposure to short
wavelength visible light. The ﬁnding that serum zeaxanthin
may be more important than serum lutein in any protection
conferred against ARM is also consistent with the recent
report by Gale et al. [174]. In the cross-sectional arm of
the Rotterdam Eye Study, no association between ARM and
serum levels of either beta-carotene or lutein or zeaxanthin
was observed [235].
In summary, the relationship between ARM and dietary
intake (and serum levels) of macular carotenoids remains
unclear. However, recent reports from AREDS and the Blue
Mountains Eye Study do suggest that dietary intake of lutein
and zeaxanthin may be protective for ARM.Journal of Ophthalmology 21
Table 12: Studies investigating the relationship between dietary and serum levels of carotenoids and risk for ARM.
Study No. of cases Measure of risk factor Type of ARM Odds ratio or relative
risk
95% conﬁdence
interval
Cross-Sectional Studies
National Health and
Nutrition Examination
Survey III [245]
8222
Dietary intake of
lutein and zeaxanthin
Pigmentary
abnormalities
0.1 (Younger age
groups) 0.1–0.3
Serum level of lutein
and zeaxanthin Early ARM 1.0 0.6–1.5
Prospective Studies
Beaver Dam Eye Study
[237] 1709
Dietary intake of
pro-vitamin A
carotenoids
Large drusen 0.53 0.3–1.0
0.45 0.2–1.0
Blue Mountains Eye Study
[226, 242]
2900 Dietary intake of
carotene
Early ARM 0.7 0.4–1.1
Late ARM 0.7 0.3–2.0
Blue Mountains Eye Study
[226, 242]
1989 Dietary intake of α-
and β-carotene Early ARM 1.3 (α-carotene) 0.8–2.2
1.2 (β-carotene) 0.7–2.1
Rotterdam Study [235] 4170
Dietary intake of
β-carotene in
combination with
vitamin C, vitamin E
and zinc
Early and late
ARM 0.65 0.46–0.92
Pathologies Oculaires Liees
aL ’ A g e[ 246]
899
Plasma Levels of
zeaxanthin
Early and Late
ARM 0.07 0.01–0.58
Combined plasma
level of lutein and
zeaxanthin
Early and late
ARM 0.21 0.05–0.79
(e) Antioxidant Enzymes. Several antioxidant enzymes form
vital components of cellular defense mechanisms against
oxidative stress [173]. There is scant evidence from
population-basedepidemiologicalstudiesforanyassociation
between these enzymes and ARM. The POLA study found
that high levels of plasma glutathione peroxidase were
signiﬁcantly associated with a nine-fold decrease in the
prevalence of late ARM [29]. However, that study failed
to ﬁnd any association between high levels of superoxide
dismutase and the prevalence of either early or late ARM
[29].
(f) Zinc (Table 13). The ﬁnal aspect of antioxidant status
that has been evaluated in population-based epidemiologic
studies with respect to ARM is that of the trace element, zinc
is an essential cofactor for antioxidant enzymes. Food rich
in zinc includes meat, poultry, ﬁsh, whole grains, and dairy
products [173].
The retrospective arm of the Beaver Dam Eye Study
detected a weak protective eﬀect for individuals in the
highest quintile of dietary intake of zinc when compared
with those in the lowest quintile (Table 13)[ 234]. However,
this was conﬁrmed only for pigmentary macular changes in
the prospective arm of that study [234]. Of note, the Blue
Mountains Eye Study found no association between dietary
intake of zinc and either the prevalence or incidence of ARM
[226]. In contrast, the Rotterdam Study reported that a high
dietary intake of zinc had a protective eﬀect for the incidence
of ARM [235].
5.2.2. Pro-Oxidant Status. Aspects of pro-oxidant status
that have been evaluated with respect to risk for ARM in
population-based epidemiologic studies include exposure to
light and dietary intake of fatty acids.
(a) Dietary Intake of Fatty Acids (Table 14). Polyunsaturated
fatty acids are particularly susceptible to free radical damage,
and it is noteworthy that the photoreceptor membranes
of both rods and cones contain a lipid bilayer [224].
Polyunsaturated fatty acids account for about 50% of the
lipid bilayer of rod outer segment membranes, and the
concentrations of these molecules within this layer can be
altered by dietary modiﬁcation [224]. Therefore, dietary
intake of fatty acids may be associated with ARM by enhanc-
ing the vulnerability of rod outer segment membranes
to oxidative damage [254, 256]. However, animal studies
have shown that certain polyunsaturated fats, particularly
docosahexaenoic acid, may actually confer resistance against
retinal oxidation, probably because they replenish these
compounds inthephotoreceptormembranesfollowingtheir
depletion by free radical injury [224]. Docosahexaenoic acid
is found predominantly in oily ﬁsh and oﬀal [224]. Dietary
intake of saturated fats could be etiologically important for
the development of ARM because of the eﬀect of such intake
on cholesterol levels within the bloodstream or within the
tissue, or through eﬀects on the inﬂammatory cascade.
A number of studies have investigated dietary intake of
total fat, saturated fat, and polyunsaturated fat with respect
to ARM (Table 14). Further, some of these studies have also22 Journal of Ophthalmology
Table 13: Studies investigating the relationship between zinc and risk for ARM.
Study No. of cases Measure of risk factor Type of ARM Odds ratio or relative
risk
95% conﬁdence
interval
Cross-Sectional Studies
Beaver Dam Eye Study
[234]
1968 Dietary intake Early ARM 0.6 0.4–1.0
Beaver Dam Eye Study
[234, 237]
1709 Dietary intake Early ARM 0.7 0.5–1.0
Late ARM 1.1 0.3–4.1
Blue Mountains Eye Study
[233] 2900 Dietary intake Early ARM 0.8 0.5–1.3
Late ARM 1.0 0.4–2.8
Blue Mountains Eye Study
[226, 233]
1989 Dietary intake Early ARM 1.3 0.7–2.7
Rotterdam Study [235] 4170 Dietary intake Early and late
ARM 0.91 0.83–0.98
Table 14: Studies investigating the relationship between dietary fat/ﬁsh intake and risk for ARM.
Study No. of cases Measure of risk factor Type of ARM Odds ratio or relative
risk
95% conﬁdence
interval
Cross-Sectional Studies
National Health and
Nutrition Examination
Survey III [56]
7883
Total fat intake
(percentage of total
energy)
Early ARM 1.4 0.9–2.2
Late ARM 0.7
0.2–2.6 (>60
years of age)
Blue Mountains Eye Study
[253]
2900
Energy-adjusted
intake of cholesterol Late ARM 2.71 0.93–7.96
Frequency of ﬁsh
consumption per
week
Late ARM
0.52 0.22–1.24
(1/wk)
0.47 0.20–1.11
(2–4/wk)
0.46 0.12–1.68
(>5/wk)
Prospective Studies
Beaver Dam Eye Study
[254]
2152 Saturated fat %kJ Early ARM 1.8 1.2–2.7
Cholesterol
Mg/4200kJ Early ARM 1.6 1.1–2.4
Blue Mountains Eye Study
[255]
2335
Total dietary fat Early ARM 0.92 0.53–1.59
Late ARM 1.19 0.36–3.94
Frequency of ﬁsh
consumption per
week
Early ARM 0.58 0.37–0.90
(1/wk)
Late ARM 0.25 0.06–1.00
(3/wk)
speciﬁcally investigated dietary intake of ﬁsh and ﬁsh oils
with respect to risk for ARM. Cross-sectional evidence from
the Beaver Dam population suggested that high intake of
saturated fats and cholesterol was associated with increased
prevalence of early ARM [254]. In NHANES III, similar
relationships between total fat intake and early ARM were
seen, but these did not reach statistical signiﬁcance [56]. In
the Blue Mountains population, a signiﬁcant, but marginal,
relationship between total dietary intake of fat and early
ARM was initially detected [253, 255]. More recently, data
from the Blue Mountains Eye Study failed to detect an
association between high dietary intake of total fat, or
subtypes of fat, and the incidence of ARM (early or late)
[253]. However, the Blue Mountains Eye Study did reveal a
protective, albeit weak, eﬀect of dietary intake of ﬁsh for the
incidence of late ARM [253, 255].
(b) Light (Table 15). The retina is subjected to high levels
of cumulative irradiation with visible light over a lifetime.
Exposuretoambientlightisknowntoresultinretinalinjury,
and a number of laboratory studies indicate that oxidative
stress plays a role in this process [173]. Furthermore, the
vulnerability of the retina to damage by visible light varies
with the wavelength of the incident light, and it has beenJournal of Ophthalmology 23
Table 15: Studies investigating the relationship between cumulative sunlight exposure and risk for ARM.
Study No. of cases Measure of risk factor Type of ARM Odds ratio or relative
risk
95% conﬁdence
interval
Cross-Sectional Studies
Beaver Dam Eye Study
[260]
4926
Amount of time spent
outdoors in summer
Retinal
pigmentary
changes
1.44 1.01–2.04 (men)
Amount of leisure
time spent outdoors
in summer
Late ARM 2.19 1.12–4.25 (men)
Pathologies Oculaires Liees
aL ’ A g e[ 262]
2584
Ambient solar
Radiation Early ARM 0.73 0.54–0.98
Leisure exposure to
sunlight Early ARM 0.80 0.64–1.00
Prospective Studies
Beaver Dam Eye Study
[261]
3684
Amount of leisure
time spent outdoors
aged 13–19 years and
aged 30–39 years
Early ARM 2.09 1.19–3.65
Beaver Dam Eye Study
[258] 2764
Amount of leisure
time spent outdoors
aged 13–19 years,
aged 30–39 years and
at baseline
examination
Early ARM 2.20 1.02–4.73
Average annual UV-B
exposure
Early ARM 0.83 0.62–1.10
Late ARM 1.00 0.54–1.82
shown that the power required to cause photo-oxidative
retinal damage is up to 1000 times lower for blue-light
than for infrared wavelengths, depending on the duration
of exposure [257–259]. On this basis, it has been postulated
that cumulative exposure to visible light, especially (short-
wavelength) blue-light, is etiologically important for the
pathogenesis of ARM, and this hypothesis has been explored
in a number of epidemiologic studies (Table 15).
Unfortunately, it is diﬃcult to accurately measure cumu-
lative and lifetime exposure to visible light. The Beaver Dam
Eye Study investigated how exposure to sunlight relates to
prevalence and incidence (5 and 10 years) of ARM and
found signiﬁcant associations between extended exposure
to summertime sun and the 10-year incidence of early
ARM [258, 260, 261]. The investigators did not, however,
detect any relationship between mean annual ambient UV-
B exposure and the incidence or progression of ARM at 10
years [258,260,261].IncontrasttotheﬁndingsintheBeaver
Dam Eye Study, the POLA study [30] found that sunlight
exposure was not signiﬁcantly associated with increased risk
of ARM [262]. In fact, in the POLA Study, the risk of early
ARM [262] was lower in subjects exposed to high ambient
solar radiation. In the Visual Impairment Project, people
with ARM were found to have had higher annual ocular
exposure to sunlight, but this ﬁnding was not statistically
signiﬁcant [32].
6. OcularFactors
6.1. Refractive Error (Table 16). It has been proposed that
refractive error may be etiologically important for the
development of ARM [267].
6.1.1. Hypothesis/Rationale. The pathophysiologic mecha-
nisms for any association between refractive error and ARM
remain unclear. Hypermetropic eyes typically have a smaller
axial length than emmetropic or myopic eyes, and have
a tendency towards increased scleral thickness [267, 268].
These factors may contribute to an increased scleral rigidity
inhypermetropiceyes,whichmay,inturn,beassociatedwith
an increase in the resistance of choroidal venous outﬂow and
therefore be consistent with the vascular hypothesis of ARM
pathogenesis [267, 268].
6.1.2. Epidemiologic Studies. A number of case-control stud-
ies have looked at the association between hypermetropia
and ARM [121]. However, the results have been inconsistent.
A small number of population-based studies have also
examined the relationship between hypermetropia and ARM
(Table 16). In these studies, autorefractor readings and
subjective refraction were used to assess spherical equivalent
refractive error (in diopters). In 1998, the Blue Mountains
EyeStudyshowedaweakassociationbetweenhypermetropia24 Journal of Ophthalmology
Table 16: Studies investigating the relationship between refractive error and risk for ARM.
Study No. of cases Measure of risk factor Type of ARM Odds ratio or relative
risk
95% conﬁdence
interval
Cross-Sectional Studies
Blue Mountains Eye Study
[263]
3654
Each diopter of
increase in mean
spherical equivalent
Early ARM 1.1 1.0–1.2
Late ARM 1.0 0.9–1.1
Rotterdam Study [264] 6209
Each diopter of
increase towards
hypermetropia
Early ARM 1.09 1.04–1.14
Late ARM 1.09 1.01–1.19
Beijing Eye Study [37] 4439 Hypermetropia Early ARM N/A 1.1–1.34
Late ARM 0.76–1.05
Prospective Studies
Blue Mountains Eye Study
[265]
2335
Each diopter of
increase in mean
spherical equivalent
Early ARM 1.1 0.98–1.15
Late ARM 1.1 0.9–1.2
Beaver Dam Eye Study
[266] 3684 Hypermetropia +1.00
diopter or more
Early ARM 0.86 0.62–1.19 (Right
Eye)
0.75 0.55–1.03 (Left
Eye)
Late ARM 2.09 0.30–14.49
(Right Eye)
3.56 0.59–21.74 (Left
Eye)
Beaver Dam Eye Study
[266] 3306 Hypermetropia +1.00
diopter or more
Early ARM 0.9 0.7–1.1
Late ARM 1.2 0.6–2.3
Rotterdam Study [264] 4935
Each diopter of
increase towards
hypermetropia
Early and late
ARM 1.05 1.01–1.10
and early ARM only [263]. However, ﬁve-year followup
of the same study failed to show any association between
hypermetropia and the incidence of either late or early ARM
[265].
Similarly, the Beaver Dam Eye Study failed to identify a
relationship between refractive status and either the 5-or 10-
year incidence of ARM (early or late) [266]. In contrast to
this, the Rotterdam study demonstrated that hypermetropia
was associated with an increased prevalence of ARM, and,
to a slightly lesser extent, with an increased incidence of
ARM [264]. Indeed, this study showed that, for each diopter
increase in hypermetropia, there was a 5% increase in the
riskofdevelopingincidentARM.Finally,cross-sectionaldata
from the Beijing Eye Study revealed that (other than age)
hypermetropicrefractiveerrorwasthesinglemostimportant
risk factor for ARM [37].
6.2. Iris Color (Table 17). Iris color is related to skin pigmen-
tation, and therefore a relationship, if any, between iris color
and ARM must be interpreted with full appreciation of the
possibility that any observed association between iris color
and ARM may actually reﬂect ethnicity-based diﬀerences for
this condition.
6.2.1. Hypothesis/Rationale. Subjects with nonblue irides
have increased tissue concentrations of melanin, and this
is also evident in the choroid [275, 276]. It has been
hypothesized that choroidal melanin may protect against
oxidative damage from sunlight, thus providing protection
to the retina and reducing the risk of ARM [275, 276].
Heavy iris pigmentation has also been shown to reduce the
amount of light entering the eye [275, 276], and this is
another possible protective mechanism. Also, some papers
have reported that light iris color is associated with a
relativelackofmacularpigment,andsomeinvestigatorshave
speculated that this relative lack of antioxidant defenses in
the central retina may also explain any increased risk for
ARM in association with light iris color [275, 276].
6.2.2. Epidemiologic Studies. Initial case-control studies sug-
gested that brown-colored irides were associated with a
r e d u c e dr i s kf o rA R M[ 276]. In 1990, however, the ﬁrstJournal of Ophthalmology 25
Table 17: Studies investigating the relationship between iris color and risk for ARM.
Study No. of cases Measure of risk factor Type of ARM Odds ratio or relative
risk
95% conﬁdence
interval
Cross-Sectional Studies
Copenhagen City Eye Study
[269]
924 Brown versus blue iris
color
Drusen and
decreased vision 0.7 N/A
Blue Mountains Eye Study
[270]
3654 Blue versus brown iris
colour
Early ARM 1.45 1.1–1.9
Late ARM 1.69 1.0–2.9
Early ARM 1.06 0.76–1.47 (Right
eye)
1.15 0.85–1.56 (Left
eye)
Prospective Studies
Beaver Dam Eye Study
[271]
3684 Brown iris Color Late ARM 1.61 0.60–4.33 (Right
eye)
0.99 0.41–2.37 (Left
eye)
Beaver Dam Eye Study
[271]
2764 Blue versus brown iris
color
Soft indistinct
drusen 1.53 1.19–1.97
Retinal pigment
abnormalities 0.58 0.41–0.82
population-based study investigating this found no signiﬁ-
cant diﬀerence in the prevalence of ARM between partici-
pants with brown- or blue-colored irides (Table 17)[ 269].
Indeed, initial evidence from the Beaver Dam Eye Study
also suggested the absence of any signiﬁcant association
between iris color and risk for ARM [21]. However, in 1998,
cross-sectional data from the Blue Mountains Eye Study
reported that blue iris color was signiﬁcantly associated
with an increased risk of both early and late ARM when
compared with dark irides [270, 275]. Then, a second and
prospectivepaperfromtheBeaverDamEyeStudy,published
in 2003, demonstrated that people with brown irides were
signiﬁcantly more likely to develop soft indistinct drusen,
but less likely to develop retinal pigment epithelial changes,
than those with light irides at ﬁve-year followup [271, 275].
However, this paper did not show any association between
iris color and the development of late ARM [271, 275].
There is a strong correlation between hair color and iris
color, thus prompting a number of researchers to investigate
hair color with respect to risk for ARM. The Beaver Dam Eye
Study showed that people with brown hair were less likely to
developearlyARM,intheformofpigmentaryabnormalities,
when compared to those with blond hair [271, 275]. In
that study, however, hair color was not associated with the
development of late ARM [271, 275].
6.3. Cataract and Cataract Surgery (Tables 18 and 19).
Cataract and ARM are the most frequent causes of decreased
vision in older people. Of the numerous cataract subtypes,
the most commonly seen are nuclear sclerosis, cortical
lens opacities, and posterior subcapsular cataracts. The
prevalence of lens opaciﬁcation rises with increasing age
and may therefore have risk factors common with ARM.
Alternatively, cataracts could, in theory at least, have a
protective eﬀect against ARM due to their light-absorbing
properties.
6.3.1. Hypothesis/Rationale. It has been hypothesized that
cataracts may provide protection against ARM by absorbing
blue light, and thus reducing oxidative damage to the retina
[281–284]. However, this protective eﬀect, if any, would
be restricted to certain types of cataract, such as nuclear
sclerosis.
As sunlight has been putatively implicated in the
pathogenesis of ARM, the possibility that cataract surgery
results in increased risk of ARM has been postulated.
Indeed, ophthalmologists often observe the development
of neovascular AMD shortly following cataract surgery.
Such a hypothesis has prompted lens manufacturers to
incorporate a blue-light ﬁlter into the intraocular lens.
However, the beneﬁt of such blue-ﬁltering intraocular lenses
has yet to be established [281, 282]. Cataract surgery is also
associated with intraocular inﬂammatory changes, which
may be associated with progression of ARM. Alternatively,
any association between ARM and cataract surgery may
simplybeduetothefactthatidentiﬁcationofARMmayhave
gone unnoticed preoperatively, because of impaired fundus
visualization attributable to the lens opacity.
6.3.2. Epidemiologic Studies. Early population-based epi-
demiological studies have reported inconsistent ﬁndings
on the relationship between cataract and ARM (Table 18).
Cross-sectional data from the Framingham Eye Study
reported that nuclear sclerosis was negatively associated
with ARM, but that cortical lens opacities were positively
associated with this condition [52, 53]. In the National
Health and Nutrition Examination Survey I, subjects with26 Journal of Ophthalmology
Table 18: Studies investigating the relationship between cataract and risk for ARM.
Study No. of cases Measure of risk factor Type of ARM Odds ratio or relative
risk
95% conﬁdence
interval
Cross-Sectional Studies
Framingham Eye Study
[52, 53]
Nuclear sclerosis Early and late
ARM <1.00 (All ages) N/A
Cortical lens opacity Early and late
ARM >1.00 (Age 52–74) N/A
National Health and
Nutrition Examination
Survey I [54]
3087
Opacity without
visual impairment ARM 1.80 1.40–2.30
Cataract ARM 1.14 0.84–1.55
Blue Mountains Eye Study
[272] 3654
Nuclear Sclerosis Early ARM 1.0 0.6–1.9
Late ARM 1.6 0.5–5.3
Cortical lens Opacity Early ARM 1.4 0.9–2.2
Late ARM 1.7 0.7–4.2
Posterior Subcapsular
lens Opacity
Early ARM 1.1 0.4–2.7
Late ARM 3.0 1.0–9.3
Beaver Dam Eye Study
[273] 4926 Nuclear sclerosis Early ARM 1.96 1.28–3.01
Late ARM 1.38 0.52–3.63
ProspectiveStudies
Beaver Dam Eye Study
[181, 273, 274]
2764 Any lens opacity Early ARM 1.30 1.04–1.63
Copenhagen City Eye Study
[38–40]
359 Any lens opacity Early and late
ARM 2.8 1.2–6.2
Table 19: Studies investigating the relationship between cataract surgery and risk for ARM.
Study No. of cases Measure of risk factor Type of ARM Odds ratio or relative
risk
95% conﬁdence
interval
Cross-Sectional Studies
Salisbury Eye Evaluation
Project + Proyecto VER +
Baltimore Eye Survey
(Pooled data) [277]
2520 + 4774 + 4396 Previous cataract
surgery Late ARM 1.7 1.1–2.6
Andhra Pradesh Eye Study
[41]
3723 Previous cataract
surgery
Early and late
ARM 3.79 2.1–6.78
Prospective Studies
Beaver Dam Eye Study
[278]
3684 Previous cataract
surgery Late ARM 2.80 1.03–7.63
Beaver Dam Eye Study
[278] 2764 Previous cataract
surgery
Early ARM 1.36 0.82–2.23
Late ARM 3.81 1.89–7.69
Blue Mountains Eye Study
+ Beaver Dam Eye Study
(Pooled data) [279]
3684 + 2335 Previous cataract
surgery Late ARM 5.7 2.4–13.6
Blue Mountains Eye Study
[280]
1952 Previous cataract
surgery Late ARM 3.3 1.1–9.9
eitherformofcataractwereatincreasedriskfordevelopment
of ARM [54]. The inconsistencies reported earlier may be
due, in part, to the lack of any objective means of recording
or grading the lens opacities in these studies.
However, these limitations have been addressed in more
recent studies. In 1994, the Beaver Dam Eye Study published
evidence indicating that nuclear sclerosis was associated with
an increased prevalence of early ARM, but not of late ARM
[273, 274]. The investigators did not, however, ﬁnd any
relationship between either cortical or posterior subcapsular
cataracts and ARM (early or late). In 2002, the investigators
went on to show that nuclear sclerosis at baseline wasJournal of Ophthalmology 27
Table 20: Studies investigating the relationship between alcohol and risk for ARM.
Study No. of cases Measure of risk factor Type of ARM Odds ratio or relative
risk
95% conﬁdence
interval
Cross-Sectional Studies
Beaver Dam Eye Study
[285]
4926 Consumption of beer
in the past year
Pigmentary
changes 1.13 1.02
Neovascular
AMD 1.41 1.41
Blue Mountains Eye Study
[286] 3654
Consumption of
spirits Early ARM 1.61 1.07–2.41
Consumption of beer Early ARM 1.42 0.86–2.35
Late ARM 0.89 0.32–2.48
National Health and
Nutrition Examination
Survey 1 [287]
3072 Consumption of wine Early and Late
ARM 0.81 0.67–0.99
Los Angeles Latino Eye
Study [114]
5875
“Heavy”
consumption of
alcohol (>5 drinks
per session)
Geographic
atrophy 12.7 1.5–104.6
Neovascular
AMD 5.8 1.3–25.8
Andhra Pradesh Eye Study
[41]
3723
“Light” alcohol
drinkers versus
non-drinkers
Early and late
ARM 0.38 0.19–0.76
Prospective Studies
Beaver Dam Eye Study
[116, 288]
3534
Consumption of
>78g/wk of alcohol
from beer versus
0g/week beer
consumption
Early ARM N/A
N/A [Power
0.08 (10.6%
Incidence versus
6.9%
Incidence)]
Reykjavik Eye Study
[34, 35]
846 Current alcohol
consumption Soft drusen 0.48 0.28–0.82
(<Monthly)
0.34 0.16–0.72
(>Monthly)
Copenhagen City Eye Study
[38, 39]
359 Alcohol consumption
>250g/wk Early ARM 4.6 1.1–19.2
associated with an increased 10-year incidence of early ARM,
but no association with the incidence of late ARM was
reported [20, 273, 274]. In 2005, the Copenhagen City Eye
Study demonstrated a positive association between baseline
cataract and the 14-year incidence of ARM [38–40]. In
contrast to the earlier studies, however, the Blue Mountains
Eye Study found no association between the presence of
cortical, nuclear, or posterior subcapsular cataract and ARM
(either early or late) [272].
Evidence for a relationship between cataract surgery and
ARM is, however, more consistent (Table 19). A single large
population-based study reported no association between
cataract surgery and ARM, but most other studies have
shown some association [278, 279]. Pooled data from the
Salisbury Eye Evaluation, the Proyecto VER, and the Balti-
more Eye Survey showed that cataract surgery at baseline
examination was associated with an increased prevalence
of late ARM [277]. Evidence from the population-based
Andhra Pradesh Eye Disease Study also demonstrated an
association between prior cataract surgery and prevalence of
ARM [41]. Indeed, longitudinal data from the Beaver Dam
EyeStudyhasalsodemonstratedarelationshipbetweenprior
cataract surgery and the incidence of late ARM at both 5-
and 10-year followup [278]. However, this latter study did
not ﬁnd a relationship between prior cataract surgery and
incidence of early ARM. When 5-year incidence data from
the Beaver Dam Eye Study was pooled with similar data from
the Blue Mountains Eye Study, pseudophakic and aphakic
eyes were at nearly six-fold increased risk for developing late
ARM when compared with phakic eyes [277]. Furthermore,
10-year followup in the Blue Mountains Eye study revealed
that pseudophakic eyes had a three-fold increased risk of
developinglateARMwhencomparedwithphakiceyes[280].
However,itshouldbenotedthatarecentreportfromAREDS
data failed to detect an association between cataract surgery
and ARM [121, 280].
In conclusion, the relationship between cataract and
cataract surgery and AMD has been the subject of much
debate over recent years. With regard to cataract and ARM,
some studies show cataract to be negatively associated
with ARM, others having equivocal results. With regard
to cataract surgery and ARM, some studies show it to be28 Journal of Ophthalmology
beneﬁcial in AMD patients, whereas others show cataract
extraction to have deleterious eﬀects and result in progres-
sionofdisease.Atthistimehowever,itisnotpossibletodraw
reliable conclusions from the available data to determine
whether cataract surgery is beneﬁcial or harmful in people
with AMD. Physicians will have to make practice decisions
based on best clinical judgment until appropriate studies are
conducted and reported.
7.MiscellaneousFactors
7.1. Alcohol Consumption (Table 20). The association, if
any, between alcohol consumption and ARM has been
investigated in a number of studies.
7.1.1. Hypothesis/Rationale. Alcohol has been shown to have
both harmful and beneﬁcial eﬀects with respect to a number
ofconditions,andmayexertdeleteriouseﬀectsbyinterfering
with cellular defense mechanisms against oxidative processes
[289, 290].
However, investigation of the association between alco-
hol and cardiovascular disease has also revealed a number
of mechanisms whereby alcohol may actually exert beneﬁcial
eﬀects. Putative mechanisms leading to a protective eﬀect of
alcoholincludeincreasedHDLcholesterol,decreasedplatelet
aggregation [289, 290], and decreased levels of ﬁbrinogen.
Indeed, diﬀerent forms of alcoholic beverage may exert
diﬀerent inﬂuences. Wine has high concentrations of phe-
nolic compounds, and these are thought to have beneﬁcial
eﬀects.Beer,ontheotherhand,containsnitrosamines,which
may exert toxic eﬀects. However, when investigating the
relationshipbetweenalcoholandARM,itshouldbebornein
mind that alcohol consumption is also an indicator of other
lifestyle and dietary variables.
7.1.2. Epidemiologic Studies. Initial evidence from the Beaver
Dam Eye Study revealed that consumption of beer in the
past year was associated with an increased prevalence of
pigmentary changes at the macula, and of neovascular
AMD (Table 20)[ 285]. However, the investigators did not
ﬁnd any association between current consumption of wine
or liquor with early or late ARM. The 5-year incidence
data from this study subsequently showed that, with the
exceptionofanassociationbetweenbeerdrinkingandretinal
drusen in men only, consumption of alcoholic beverages
was unrelated to risk for ARM [288]. However, 10-year data
from the same study detected an association between heavy
alcohol consumption and incident late ARM [116]. The
Blue Mountains Eye Study found a signiﬁcant and positive
association between consumption of liquor and early ARM,
butnolinkbetweenbeerconsumptionandearlyARM[286].
NHANES I reported that moderate wine consumption was
associated with a protective eﬀect against the development of
ARM (unspeciﬁed whether early or late) [287].
Other studies have also investigated the eﬀects of total
alcohol consumption with respect to age related macu-
lopathy. Cross-sectional data from the Reykjavik Eye Study
found that current alcohol consumption was associated with
decreased risk of drusen formation, and increased risk of
pigmentarychanges,atthemacula[34,35].TheCopenhagen
City Eye Study found that excessive alcohol consumption
increased the risk of early ARM [38, 39]. Similarly, cross-
sectional data from Los Angeles Latino Eye Study found
that heavy drinking was associated with increased risk of
retinal pigment epithelial depigmentation and with a higher
prevalence of late ARM (atrophic or neovascular) [114].
The Andhra Pradesh Eye Study found that the prevalence of
ARM was signiﬁcantly lower in light-alcohol drinkers when
compared with nonalcohol drinkers [41].
7.2. Medication Use. The association between use of certain
medications and risk of ARM has been investigated in a
number of population-based epidemiologic studies [23].
7.2.1. Hypothesis/Rationale. Certain medications, such as
chloroquine and chlorpromazine, are well known to have
toxic eﬀects on the human retina [291]. It is biologically
plausible, therefore, that the use of medications may be
relevant to the risk of developing retinal disease, such as
ARM. However, study of the association between medication
use and ARM may also reﬂect an association between
ARM and the disease for which the medication has been
prescribed.
7.2.2.EpidemiologicStudies. Areviewofstudiesinvestigating
the relationship between ARM and hormone replacement
therapyandlipid-loweringagentshasalreadybeendiscussed.
The Beaver Dam Eye Study investigated the association,
if any, between medication use and the 5-year incidence
of early ARM [168]. There was no detectable relationship
between early ARM and intake of the following medications:
most antihypertensive drugs, most central nervous system
medications, nonsteroidal anti-inﬂammatory medications,
estrogens. and lipid lowering agents. However, the inves-
tigators did report a protective eﬀect of antidepressants
with respect to the incidence of early ARM [168]. The
Blue Mountains Eye Study failed to detect an association
between the use of systemic anti-inﬂammatory medications
and the prevalence or incidence of ARM [196]. In the Visual
Impairment Project, past or current use of angiotensin-
converting enzyme inhibitors was associated with increased
risk of both early and late ARM [32]. However, these
ﬁndings were not adjusted for blood pressure readings, as
this information was not available for that study.
Due to the diﬃculties and limitations in the studies
designed to investigate associations between medication
usage and ARM, data from the Beaver Dam Eye Study,
the Blue Mountains Eye Study, and the Rotterdam Study
has been pooled [26]. This pooled data failed to reveal a
strong association between usage of any medicines and the
incidence of early ARM [26]. However, pooling of the data
revealedaslightlyincreasedriskofearlyARMamongusersof
β-blockers,andareducedriskofearlyARMamongstusersof
hormone replacement therapy and tricyclic antidepressants.
However, it should be emphasized that these latter ﬁndings
were of borderline signiﬁcance.Journal of Ophthalmology 29
7.3. Coﬀee Consumption. Intake of caﬀeine has been shown
to have a vasoconstrictive eﬀect on the retinal capillary
circulation at the macula [292], thus prompting the notion
that cumulative intake of coﬀee is associated with risk for
ARM (in view of the vascular hypothesis for this condition).
T h eB e a v e rD a mE y eS t u d yi n v e s t i g a t e dc o ﬀee consumption
with respect to risk for ARM [293], and it was reported that
coﬀeeandcaﬀeineconsumptionwerenotassociatedwiththe
5-year incidence of early ARM.
7.4. Frailty. ARM can also be considered to be part of a
globalagingprocess,aswellasaspeciﬁcdiseaseentity.Inthis
context, markers of frailty or biologic aging may be relevant
to risk for ARM. Such markers include gait-time, handgrip
strength, peak expiratory ﬂow rate, and the ability to stand
from a sitting position without using the arms. The Beaver
Dam Eye Study has examined the relationship between these
markers and ARM [223], and the investigators reported a
weak but signiﬁcant association between handgrip strength
and risk for ARM in men (after adjusting for comorbidity).
The investigators proposed therefore that ARM should
probably be viewed as a speciﬁc disease process (albeit age-
related).
8. Conclusion
Meaningful comment on risk for ARM has been greatly
facilitated by a large number of studies of varying design
that have been published over the last twenty years. Our
review of case series, large-scale population-based studies,
cohort, cross-sectional, and case-control studies strongly
indicate that age, tobacco use, and family history of ARM
represent indeed the risk for this condition. Further, there is
a growing body of evidence that cataract surgery and obesity
also represent risk for ARM, especially the neovascular form
of this disease.
However, population-based epidemiologic studies have
failedtoconsistentlydemonstrateassociationsbetweenARM
and a myriad of other potential risk factors. It should
be noted that the low prevalence of late ARM in the
general population makes the detection of relationships
with potential risk factors for its development particularly
diﬃcult in the context of population-based studies. More-
over, identiﬁcation of relationships may also be confounded
where disease expression is strongly determined by genetic
background. Indeed, our recently enhanced understanding
of the genetic basis of ARM will inform the design and
interpretation of future studies attempting to investigate risk
for ARM, and the role of gene-environment interaction in
the etiopathogenesis of this condition.
Methodof LiteratureSearch
References for this review were identiﬁed through a com-
prehensive systematic literature search of the electronic
MEDLINE database (1966–2008) using the Pubmed search
service. Further articles, abstracts, and textbook references
generated from reviewing the bibliographies of the initial
search were selectively included. To ensure the up-to-date
nature of our review article, current issues of Archives of
Ophthalmology, Survey of Ophthalmology, American Journal
ofOphthalmology,Ophthalmology,BritishJournalofOphthal-
mology, and Investigative Ophthalmology and Visual Sciences
were regularly reviewed throughout the period of writing.
The following key words, and combinations thereof, were
used to perform the initial search: age-related maculopathy,
agerelated macular degeneration, risk factors, epidemiology,
family history, smoking, cardiovascular disease, inﬂammation,
oxidative stress,cataract,iriscolor, refractiveerror,andalcohol.
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